,news_time,Positive,Negative,Polarity,Subjectivity,news_tag,news_title,news_link
0,2022-11-18,400.0,121.0,0.5355086362082367,0.23660308799427654,Vaccines,Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-report-new-data-omicron-ba4ba5-adapted
1,2022-11-11,84.0,10.0,0.7872340341783614,0.2625698316687994,Financial,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-12
2,2022-11-10,407.0,108.0,0.5805825231445,0.24535493080259413,Vaccines,Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-1
3,2022-11-04,450.0,126.0,0.5624999990234375,0.23021582724611678,COVID-19,Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-clinical-data-omicron
4,2022-11-01,,,,,Financial,PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-strong-third-quarter-2022-results-and-raises
5,2022-11-01,244.0,76.0,0.524999998359375,0.24902723716029007,Vaccines,Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-global
6,2022-10-13,465.0,111.0,0.6145833322663484,0.23300970864360449,Vaccines,Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-early-data-clinical
7,2022-10-12,423.0,112.0,0.5813084101283955,0.23980277891537305,Vaccines,Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use-1
8,2022-10-05,225.0,68.0,0.5358361756456104,0.27589453834661526,Financial,Pfizer Completes Acquisition of Global Blood Therapeutics,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-global-blood-therapeutics
9,2022-10-04,307.0,145.0,0.3584070788530817,0.24672489069501916,Research and Pipeline,Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-topline-results-phase-3-talapro-2
10,2022-10-03,178.0,52.0,0.5478260845746692,0.24546424733675107,Financial,Pfizer Completes Acquisition of Biohaven Pharmaceuticals,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-biohaven-pharmaceuticals
11,2022-09-26,421.0,111.0,0.5827067658219798,0.2386720501396716,Vaccines,Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-application-us-fda-emergency-0
12,2022-09-22,46.0,4.0,0.8399999832000004,0.3067484643757763,Financial,Pfizer Declares Fourth-Quarter 2022 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2022-dividend
13,2022-09-22,423.0,126.0,0.5409836055719789,0.2719167903556628,Prescription Medicines,Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-supply-global-fund-6-million-paxlovidtm-treatment
14,2022-09-20,90.0,10.0,0.799999992,0.26666666595555555,Financial,Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-november-1
15,2022-09-19,210.0,58.0,0.5671641769881933,0.25818882441407626,Research and Pipeline,Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study-0
16,2022-09-15,228.0,63.0,0.5670103073298615,0.22247706405009396,Vaccines,Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-trial-0
17,2022-09-14,76.0,12.0,0.7272727190082646,0.2634730531033741,Financial,Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-analyst-and
18,2022-09-14,200.0,39.0,0.6736401645454386,0.25978260841327977,Research and Pipeline,Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-phase-3-study-mrna-based-influenza-vaccine
19,2022-09-12,450.0,108.0,0.6129032247080587,0.23211314466218255,Vaccines,Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-0
20,2022-09-09,140.0,52.0,0.45833333094618056,0.24999999967447917,Prescription Medicines,FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata,https://www.pfizer.com//news/press-release/press-release-detail/fda-and-ema-accept-regulatory-submission-pfizers
21,2022-09-07,172.0,51.0,0.5426008944277987,0.24186550949906127,Vaccines,FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women,https://www.pfizer.com//news/press-release/press-release-detail/fda-grants-breakthrough-therapy-designation-pfizers-group-b
22,2022-09-06,87.0,11.0,0.7755101961682633,0.26775956210994656,Financial,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-11
23,2022-09-06,74.0,6.0,0.8499999893750002,0.245398772253378,Financial,Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-10
24,2022-09-01,88.0,10.0,0.7959183592253228,0.2585751972069256,Financial,Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-two-webcasts-pfizer
25,2022-09-01,456.0,108.0,0.6170212755017354,0.2340248961684544,Vaccines,Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron
26,2022-08-31,438.0,109.0,0.6014625217523537,0.22697095426266767,Vaccines,Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-granted-fda-emergency-use-authorization
27,2022-08-26,437.0,109.0,0.6007325996323579,0.23544631296444749,Vaccines,Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-complete-submission-european-medicines
28,2022-08-25,206.0,67.0,0.5091575072924633,0.27083333306464946,Vaccines,Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-trial-older
29,2022-08-23,435.0,125.0,0.5535714275829081,0.2317880793742599,Vaccines,Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-covid-19-vaccine-data
30,2022-08-22,469.0,122.0,0.5871404389388487,0.24102773236499686,Vaccines,Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-application-us-fda-emergency-use
31,2022-08-19,86.0,9.0,0.8105263072576179,0.25956284082086656,Financial,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-9
32,2022-08-12,207.0,66.0,0.5164835145916354,0.258278145451014,Vaccines,Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study-20
33,2022-08-08,244.0,96.0,0.435294116366782,0.2748585284762663,Research and Pipeline,Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-valneva-initiate-phase-3-study-lyme-disease
34,2022-08-08,340.0,89.0,0.5850815837177585,0.2681249998324219,Financial,Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance
35,2022-08-05,429.0,170.0,0.4323873114651297,0.26753014726774,Prescription Medicines,"Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis",https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-receive-us-fda-approval
36,2022-07-28,,,,,Financial,PFIZER REPORTS SECOND-QUARTER 2022 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-second-quarter-2022-results
37,2022-06-30,580.0,228.0,0.4356435638172728,0.290647481909839,Prescription Medicines,Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-submission-new-drug-application-us-fda
38,2022-06-29,457.0,123.0,0.5758620679726516,0.24555461462931644,Vaccines,Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-new-agreement-us-government
39,2022-06-28,230.0,77.0,0.4983713338815266,0.263972484725733,Financial,Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus,https://www.pfizer.com//news/press-release/press-release-detail/roivant-and-pfizer-unveil-priovant-therapeutics-and-ongoing
40,2022-06-25,478.0,133.0,0.5646481169154696,0.24362041457590894,Vaccines,Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-omicron-adapted-covid-19
41,2022-06-24,88.0,10.0,0.7959183592253228,0.26203208486087676,Financial,Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-july-28-0
42,2022-06-23,165.0,33.0,0.6666666632996633,0.2968515737678387,Financial,Valneva and Pfizer Announce Closing of Equity Investment,https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-announce-closing-equity-investment
43,2022-06-23,46.0,4.0,0.8399999832000004,0.3067484643757763,Financial,Pfizer Declares Third-Quarter 2022 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-third-quarter-2022-dividend
44,2022-06-20,243.0,83.0,0.490797544506756,0.2772108841180179,Vaccines,Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15,https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-enter-equity-subscription-agreement-and
45,2022-06-17,442.0,136.0,0.529411763789945,0.23524623515048995,Vaccines,Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-receives-fda-emergency-use
46,2022-06-17,313.0,118.0,0.4524361938458557,0.23449401510636886,Research and Pipeline,Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-publication-lancet
47,2022-06-14,465.0,169.0,0.4668769708724338,0.2801590807423071,Prescription Medicines,Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting
48,2022-06-09,167.0,40.0,0.6135265670844128,0.2891061448476171,Financial,Pfizer Completes Acquisition of ReViral,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-reviral
49,2022-06-09,71.0,6.0,0.8441558331927814,0.2499999991883117,Finance,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-8
50,2022-06-08,86.0,10.0,0.791666658420139,0.2594594587582177,Finance,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-7
51,2022-06-06,418.0,136.0,0.5090252698393045,0.27236971471368254,Financial,Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invest-120-million-produce-covid-19-oral-treatment
52,2022-06-04,252.0,109.0,0.39612188255921915,0.2491373359219204,Prescription Medicines,"Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-overall-survival-results-phase-3-paloma-2
53,2022-06-02,311.0,152.0,0.34341252625612845,0.23490613889654685,Medicines,Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-fda-acceptance-1
54,2022-06-01,84.0,20.0,0.6153846094674557,0.21181262685985208,Investments,Pfizer Provides Update on Ownership Interest in Haleon,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-provides-update-ownership-interest-haleon
55,2022-05-31,72.0,7.0,0.8227847997115848,0.24687499922851563,Finance,Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-6
56,2022-05-25,86.0,10.0,0.791666658420139,0.2651933694331675,Finance,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-5
57,2022-05-25,241.0,32.0,0.765567762763488,0.33252131506392046,Responsibility,Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-launches-accord-healthier-world-improve-health
58,2022-05-23,440.0,127.0,0.5520282177212906,0.2432432431388918,Vaccines,"Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-demonstrates-strong-immune
59,2022-05-17,392.0,115.0,0.5463510837350077,0.23299632342233625,Vaccines,Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-granted-us-emergency-use-authorization
60,2022-05-13,375.0,101.0,0.5756302508915331,0.25185185171859686,Vaccines,Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-update-covid-19-vaccine-supply
61,2022-05-10,349.0,85.0,0.6082949294739748,0.24327354246453275,Investments,Pfizer to Acquire Biohaven Pharmaceuticals,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-biohaven-pharmaceuticals
62,2022-05-06,283.0,105.0,0.4587628854155596,0.24280350422853347,Medicines,Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-provide-update-supplemental-0
63,2022-05-03,,,,,Finance,Pfizer Reports First-Quarter 2022 Results,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-first-quarter-2022-results
64,2022-04-28,146.0,21.0,0.7485029895299222,0.3145009410273052,Finance,Pfizer Announces 2022 Shareholder Meeting Preliminary Results,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-2022-shareholder-meeting-preliminary
65,2022-04-28,46.0,4.0,0.8399999832000004,0.3067484643757763,Finance,Pfizer Declares Second-Quarter 2022 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-second-quarter-2022-dividend
66,2022-04-27,201.0,64.0,0.5169811301245996,0.2644710576202884,Medicines,Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biohavens-vydurar-rimegepant-granted-first-ever
67,2022-04-26,209.0,86.0,0.41694915112898595,0.2534364258991096,Partnerships,Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-report-positive-phase-2-pediatric-data
68,2022-04-19,121.0,15.0,0.7794117589749135,0.29694323079270035,Finance,Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-shareholders-attend-virtual-only-2022-annual
69,2022-04-14,387.0,127.0,0.5058365748913686,0.22396514151461214,COVID-19,Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-data-demonstrating-high-immune
70,2022-04-12,305.0,106.0,0.4841849136637837,0.2591424966840211,Medicines,Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-provide-update-supplemental-new
71,2022-04-11,135.0,25.0,0.687499995703125,0.2807017538935057,Leadership,Pfizer Names David M. Denton Chief Financial Officer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-names-david-m-denton-chief-financial-officer
72,2022-04-07,228.0,59.0,0.5888501721642851,0.27729468572242055,Investments,Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-reviral-and-its-respiratory-syncytial-virus
73,2022-03-29,442.0,114.0,0.5899280564929351,0.23872906816714082,COVID-19,Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-expanded-us-emergency-use
74,2022-03-29,195.0,56.0,0.5537848583514547,0.2628272248556783,Medicines,"Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-yearlong-phase-3
75,2022-03-24,176.0,50.0,0.5575221214268933,0.25507900648410947,Vaccines,Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-granted-fda-breakthrough-therapy-designation-0
76,2022-03-23,168.0,59.0,0.4801762093384308,0.2837499996453125,Medicines,Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-trial
77,2022-03-22,398.0,124.0,0.5249042135538233,0.2758985199387428,COVID-19,Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-supply-unicef-4-million-treatment-courses-novel
78,2022-03-11,159.0,40.0,0.5979899467437692,0.2863309348398116,Financial,Pfizer Completes Acquisition of Arena Pharmaceuticals,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-arena-pharmaceuticals
79,2022-03-09,500.0,195.0,0.43884892023187205,0.2819472615489058,Vaccines,Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-phase-23-study-novel-covid-19-oral
80,2022-03-08,87.0,9.0,0.8124999915364585,0.258760107119245,Finance,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-4
81,2022-02-28,90.0,10.0,0.799999992,0.2702702695398101,Finance,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-3
82,2022-02-22,86.0,10.0,0.791666658420139,0.2622950812505599,Finance,Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-2
83,2022-02-14,251.0,89.0,0.47647058683391,0.2761982126107244,Research,Biohaven and Pfizer Announce Positive Top-Line Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea,https://www.pfizer.com//news/press-release/press-release-detail/biohaven-and-pfizer-announce-positive-top-line-results
84,2022-02-11,407.0,120.0,0.5445920293271499,0.2545893718576863,COVID-19,Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-update-rolling-submission
85,2022-02-09,88.0,9.0,0.8144329812945054,0.26648351575141893,Finance,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-11
86,2022-02-08,,,,,Finance,Pfizer Reports Fourth-Quarter and Full-Year 2021 Results,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-fourth-quarter-and-full-year-2021-results
87,2022-02-04,212.0,81.0,0.44709897458327996,0.25346020739320047,Research,Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-report-further-positive-phase-2-data
88,2022-02-01,447.0,125.0,0.5629370619529073,0.2526501765668506,COVID-19,Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-emergency
89,2022-02-01,101.0,28.0,0.5658914684814615,0.2544378693206354,Leadership,Pfizer Announces New Chief Development Officer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-new-chief-development-officer
90,2022-02-01,74.0,10.0,0.7619047528344672,0.27722772185733424,Responsibility,Pfizer Invites Public to View and Listen to a Webcast with Pfizer Director Joseph Echevarria to Discuss Board Oversight of ESG,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-0
91,2022-01-31,164.0,32.0,0.6734693843190338,0.25160462098638686,Partnerships,Pfizer and Ionis Announce Discontinuation of Vupanorsen Clinical Development Program,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-ionis-announce-discontinuation-vupanorsen
92,2022-01-28,307.0,116.0,0.4515366419585422,0.2680608363320273,Medicines,European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/european-commission-approves-lorviquar-lorlatinib-first
93,2022-01-27,468.0,176.0,0.45341614836426064,0.2882721574358674,COVID-19,Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-chmp-positive-opinion-novel-covid-19-oral
94,2022-01-25,367.0,114.0,0.5259875248939968,0.2547669490176022,COVID-19,Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-evaluate-omicron-based
95,2022-01-24,378.0,124.0,0.5059760946096094,0.24181117522070755,COVID-19,Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-publish-data-two-laboratory-studies
96,2022-01-21,183.0,59.0,0.5123966920975344,0.28537735815403614,Medicines,Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-opko-provide-update-biologics-license
97,2022-01-18,422.0,141.0,0.4991118996463377,0.2630841120265962,COVID-19,Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatment
98,2022-01-14,374.0,141.0,0.45242718358752004,0.26739356164725153,Medicines,U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults
99,2022-01-12,363.0,94.0,0.588621442913301,0.23459958920195093,COVID-19,Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released,https://www.pfizer.com//news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-study-exploring-0
100,2022-01-10,159.0,17.0,0.8068181772339876,0.29284525741623085,Research,Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-enters-agreement-acuitas-therapeutics-lipid
101,2022-01-10,243.0,57.0,0.6199999979333334,0.2884615381841716,Partnerships,Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research
102,2022-01-05,264.0,67.0,0.5951661613439089,0.27265238857277396,Partnerships,Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States,https://www.pfizer.com//news/press-release/press-release-detail/biohaven-and-pfizer-complete-collaboration-transaction
103,2022-01-05,209.0,46.0,0.6392156837677816,0.2704135734141956,Partnerships,Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-sign-new-global-collaboration-agreement
104,2022-01-04,407.0,127.0,0.5243445683064708,0.2721712536839086,COVID-19,Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-provide-us-government-additional-10-million
105,2022-01-04,87.0,9.0,0.8124999915364585,0.2798833811082117,Finance,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-10
106,2022-01-03,429.0,109.0,0.5947955379278893,0.2623110676439244,COVID-19,Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use-0
107,2021-12-30,85.0,9.0,0.8085106296966954,0.27728613487526216,Finance,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-9
108,2021-12-28,89.0,10.0,0.7979797899193961,0.2780898868592981,Finance,Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-february-8
109,2021-12-22,519.0,199.0,0.44568245063275425,0.2875450539497217,COVID-19,Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-us-fda-emergency-use-authorization-novel
110,2021-12-22,234.0,72.0,0.5294117629757785,0.28021977996316866,COVID-19,Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-provide-united-kingdom-additional-25-million
111,2021-12-20,228.0,62.0,0.5724137911296077,0.2361563515992212,Medicines,"Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate",https://www.pfizer.com//news/press-release/press-release-detail/pfizers-vyndaqelrvyndamaxr-reduced-risk-all-cause-mortality
112,2021-12-17,219.0,100.0,0.37304075118169044,0.2676174494399182,Medicines,"EMA Adopts a Positive CHMP Opinion for Pfizer’s and OPKO’s Somatrogon, a Long-Acting Treatment for Pediatric Growth Hormone Deficiency",https://www.pfizer.com//news/press-release/press-release-detail/ema-adopts-positive-chmp-opinion-pfizers-and-opkos
113,2021-12-17,223.0,61.0,0.5704225332027376,0.2574796008545062,Vaccines,CHMP Issues Positive Opinion for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults,https://www.pfizer.com//news/press-release/press-release-detail/chmp-issues-positive-opinion-pfizers-20-valent-pneumococcal
114,2021-12-17,293.0,118.0,0.42579075322192034,0.2655038757974781,Medicines,Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) as First-Line Treatment for ALK-Positive Advanced Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-positive-chmp-opinion-lorviquar-lorlatinib
115,2021-12-16,276.0,84.0,0.5333333318518518,0.28662420359345203,COVID-19,EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate,https://www.pfizer.com//news/press-release/press-release-detail/ema-issues-advice-potential-early-use-pfizers-novel-covid
116,2021-12-15,100.0,15.0,0.7391304283553876,0.21698113166607333,Research,"Pfizer Invests $68.5 Million in New State-of-the-Art Facility in Durham, North Carolina to Further Advance Gene Therapy Capabilities",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invests-685-million-new-state-art-facility-durham
117,2021-12-14,420.0,188.0,0.3815789467408241,0.2628620837601115,Medicines,U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment-0
118,2021-12-14,327.0,156.0,0.35403726634774896,0.28922155671304095,COVID-19,Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results
119,2021-12-13,278.0,62.0,0.6352941157785468,0.2786885243617307,Finance,Pfizer to Acquire Arena Pharmaceuticals,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-arena-pharmaceuticals
120,2021-12-12,262.0,77.0,0.5457227122545053,0.26117103215626264,Research,Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-sangamo-announce-updated-phase-12-results-1
121,2021-12-10,72.0,11.0,0.7349397501814489,0.2577639743547703,Finance,Pfizer Declares First-Quarter 2022 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-first-quarter-2022-dividend
122,2021-12-10,268.0,92.0,0.4888888875308642,0.2777777775634431,Medicines,European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/european-commission-approves-pfizers-cibinqor-abrocitinib
123,2021-12-10,317.0,144.0,0.3752711488605832,0.25122615790123914,Research,Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer,https://www.pfizer.com//news/press-release/press-release-detail/arvinas-and-pfizer-announce-protacr-protein-degrader-arv
124,2021-12-09,406.0,112.0,0.5675675664718773,0.2552981763157722,COVID-19,Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use
125,2021-12-08,414.0,122.0,0.5447761183866118,0.24519670620073344,Vaccines,Pfizer and BioNTech Provide Update on Omicron Variant,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant
126,2021-12-07,87.0,12.0,0.7575757499234773,0.26756756684441196,COVID-19,Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-register-webcast-analyst-and-0
127,2021-12-02,205.0,67.0,0.5073529393112024,0.29726775923795873,Research,AWS Helps Pfizer Accelerate Drug Development And Clinical Manufacturing,https://www.pfizer.com//news/press-release/press-release-detail/aws-helps-pfizer-accelerate-drug-development-and-clinical
128,2021-11-25,363.0,99.0,0.571428570191713,0.26101694900507516,COVID-19,Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 to under 12 Years of Age in the European Union,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion
129,2021-11-24,88.0,10.0,0.7959183592253228,0.2729805006323663,Finance,Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer
130,2021-11-24,146.0,43.0,0.5449735420900871,0.24450194017528856,Research,Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-topline-results-phase-2b-trial-vupanorsen
131,2021-11-22,390.0,104.0,0.5789473672490943,0.2613756612373674,COVID-19,Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/follow-data-phase-3-trial-pfizer-biontech-covid-19-vaccine
132,2021-11-19,213.0,51.0,0.6136363613119835,0.2926829265047861,Research,Arvinas And Pfizer Announce Updated Phase 1 Dose Escalation Data For ARV-471 To Be Presented In Spotlight Poster Session At 2021 San Antonio Breast Cancer Symposium,https://www.pfizer.com//news/press-release/press-release-detail/arvinas-and-pfizer-announce-updated-phase-1-dose-escalation
133,2021-11-19,389.0,106.0,0.5717171705621875,0.25397639802258776,COVID-19,Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-expanded-us-fda-emergency-use
134,2021-11-18,402.0,180.0,0.3814432983136713,0.2621621620440711,Medicines,Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizers-xeljanzr-tofacitinib-receives-marketing
135,2021-11-18,286.0,86.0,0.5376344071568968,0.3059210523799991,Vaccines,Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-provide-us-government-10-million-treatment-courses
136,2021-11-17,151.0,36.0,0.6149732587434585,0.28549618277023486,Finance,Pfizer Completes Acquisition of Trillium Therapeutics,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-acquisition-trillium-therapeutics
137,2021-11-17,118.0,24.0,0.6619718263241421,0.25585585539485434,Leadership,Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-retirement-chief-financial-officer-frank
138,2021-11-16,302.0,118.0,0.4380952370521542,0.3143712572497221,COVID-19,Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-seeks-emergency-use-authorization-novel-covid-19
139,2021-11-16,303.0,73.0,0.6117021260327071,0.2974683541950408,Medicines,Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-medicines-patent-pool-mpp-sign-licensing
140,2021-11-11,411.0,101.0,0.6054687488174438,0.2567703108040269,Partnerships,"Zipline, Pfizer and BioNTech Collaboration Paves the Way for Automated, On-Demand Delivery of First mRNA COVID-19 Vaccines in Ghana",https://www.pfizer.com//news/press-release/press-release-detail/zipline-pfizer-and-biontech-collaboration-paves-way
141,2021-11-10,89.0,9.0,0.8163265222823824,0.26203208486087676,Finance,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-8
142,2021-11-09,371.0,100.0,0.5753715486722473,0.2489429174159921,COVID-19,Pfizer and BioNTech Submit Request to Amend U.S. FDA Emergency Use Authorization of Their COVID-19 Vaccine Booster to Include All Individuals 18 and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-request-amend-us-fda-emergency
143,2021-11-09,261.0,71.0,0.5722891549027436,0.2707993472505715,Partnerships,Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States,https://www.pfizer.com//news/press-release/press-release-detail/biohaven-and-pfizer-enter-strategic-collaboration
144,2021-11-05,279.0,100.0,0.47229551326571106,0.30688259084462943,Research,Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study,https://www.pfizer.com//news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate
145,2021-11-02,1017.0,358.0,0.4792727269241652,0.24779239498147548,Finance,PFIZER REPORTS THIRD-QUARTER 2021 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-third-quarter-2021-results
146,2021-10-29,373.0,108.0,0.5509355497901548,0.25183246060113484,Vaccines,Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-first-us-fda-emergency-use
147,2021-10-28,392.0,104.0,0.580645160119667,0.252545824718663,Vaccines,Pfizer and BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-us-government-additional-50
148,2021-10-26,390.0,111.0,0.5568862264333608,0.2567913888996456,Vaccines,FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years,https://www.pfizer.com//news/press-release/press-release-detail/fda-advisory-committee-votes-favor-granting-emergency-use
149,2021-10-21,383.0,108.0,0.5600814652544166,0.2529623903900245,Research,Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-phase-3-trial-data-showing
150,2021-10-20,238.0,59.0,0.6026936006643313,0.23552735905192118,Vaccines,Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults,https://www.pfizer.com//news/press-release/press-release-detail/advisory-committee-immunization-practices-votes-recommend
151,2021-10-19,311.0,120.0,0.443155451407992,0.23411189558168827,Research,Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-present-data-relugolix
152,2021-10-18,323.0,96.0,0.541766108492205,0.2567401959211151,Vaccines,New Formulation of COMIRNATY® Receives Positive Opinion from CHMP,https://www.pfizer.com//news/press-release/press-release-detail/new-formulation-comirnatyr-receives-positive-opinion-chmp
153,2021-10-15,315.0,98.0,0.5254237275413469,0.252753977813492,Vaccines,Pfizer and BioNTech Submit Data to EMA for the Vaccination of Children 5 to <12 Years of Age with COMIRNATY®,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-data-ema-vaccination-children-5
154,2021-10-15,389.0,176.0,0.3769911497752369,0.25822669092402806,Medicines,Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizers-abrocitinib-receives-positive-chmp-opinion
155,2021-09-30,137.0,29.0,0.6506024057192626,0.25577811979078874,Medicines,Japan’s MHLW Approves Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/japans-mhlw-approves-pfizers-cibinqor-abrocitinib-adults
156,2021-09-29,337.0,99.0,0.5458715583810285,0.23682781084365678,Research,Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released,https://www.pfizer.com//news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-study-exploring
157,2021-09-28,196.0,96.0,0.3424657522518296,0.25840707941733887,Research,"Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate",https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-report-further-positive-phase-2-results
158,2021-09-28,325.0,104.0,0.5151515139506958,0.2485515641665402,COVID-19,Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-initial-data-us-fda-pivotal
159,2021-09-27,177.0,27.0,0.735294114042676,0.24787363274863472,Research,Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-starts-study-mrna-based-next-generation-flu-vaccine
160,2021-09-27,155.0,56.0,0.4691943105725388,0.2611386135381948,COVID-19,Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-starts-global-phase-23-epic-pep-study-novel-covid-19
161,2021-09-24,152.0,53.0,0.48292682691255207,0.26485788079475725,Medicines,Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-opko-announce-extension-us-fda-review-biologics
162,2021-09-23,46.0,4.0,0.8399999832000004,0.3067484643757763,Finance,Pfizer Declares Fourth-Quarter 2021 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2021-dividend
163,2021-09-22,365.0,96.0,0.583514098517323,0.26208072753719114,COVID-19,Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-expand-collaboration-us-provide-500
164,2021-09-20,340.0,108.0,0.5178571417012118,0.24999999986049107,COVID-19,Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results
165,2021-09-17,373.0,113.0,0.5349794227675321,0.24570272990611589,COVID-19,FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations,https://www.pfizer.com//news/press-release/press-release-detail/fda-advisory-committee-votes-unanimously-favor-comirnatyr
166,2021-09-17,279.0,158.0,0.27688787121993624,0.2629362212617712,Research,Astellas’ and Pfizer’s XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study,https://www.pfizer.com//news/press-release/press-release-detail/astellas-and-pfizers-xtandir-enzalutamide-reduced-risk
167,2021-09-09,302.0,118.0,0.4380952370521542,0.24955436705314651,Medicines,Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-fda-acceptance
168,2021-09-09,170.0,44.0,0.58878504397764,0.2736572886526122,Medicines,UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/uks-mhra-grants-marketing-authorisation-pfizers-cibinqor
169,2021-09-07,90.0,11.0,0.7821782100774435,0.2623376616562658,Finance,Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-two-webcasts-pfizer-0
170,2021-09-02,182.0,72.0,0.4330708644367289,0.298122065377791,Research,Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV),https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-start-phase-3-clinical-trial-adults-its
171,2021-08-30,157.0,51.0,0.5096153821653107,0.2733245725711898,Medicines,Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-jade-dare-trial
172,2021-08-26,109.0,24.0,0.6390977395556561,0.2872570188180194,Finance,Pfizer Announces New Chief Business Innovation Officer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-new-chief-business-innovation-officer
173,2021-08-26,374.0,100.0,0.5780590705104239,0.2645089284238231,COVID-19,Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-collaboration-brazils
174,2021-08-25,330.0,108.0,0.506849313911303,0.25614035072740327,COVID-19,Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission
175,2021-08-23,360.0,98.0,0.5720524004977022,0.25934314821101745,Vaccines,Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-comirnatyr-receives-full
176,2021-08-23,294.0,77.0,0.5849056588007934,0.24849296701373544,Finance,Pfizer to Acquire Trillium Therapeutics Inc.,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquire-trillium-therapeutics-inc
177,2021-08-20,418.0,193.0,0.36824877190139316,0.257154882046652,Medicines,XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis,https://www.pfizer.com//news/press-release/press-release-detail/xeljanzr-tofacitinib-citrate-receives-marketing
178,2021-08-16,130.0,22.0,0.7105263111149585,0.2733812944723358,Finance,Pfizer Prices $1.0 Billion Sustainability Bond,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-prices-10-billion-sustainability-bond
179,2021-08-16,323.0,102.0,0.5199999987764706,0.23624235673360625,COVID-19,Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-submission-initial-data-us-fda
180,2021-08-13,188.0,68.0,0.4687499981689453,0.2522167485199835,Vaccines,"U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine",https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-ticovactm-pfizers-tick-borne-encephalitis
181,2021-08-12,170.0,53.0,0.5246636747772929,0.25254813108431695,Vaccines,VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease,https://www.pfizer.com//news/press-release/press-release-detail/vtx-801-receives-us-fda-fast-track-designation-treatment
182,2021-08-04,135.0,69.0,0.3235294101787774,0.22054054030211834,Medicines,Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-2b3-trial
183,2021-07-28,,,,,Finance,PFIZER REPORTS SECOND-QUARTER 2021 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-second-quarter-2021-results
184,2021-07-23,309.0,91.0,0.5449999986375,0.24767801842249038,COVID-19,Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-us-government-additional-200
185,2021-07-22,327.0,133.0,0.4217391295179584,0.25641025626732983,Partnerships,Arvinas And Pfizer Announce Global Collaboration To Develop And Commercialize Protac® Protein Degrader Arv-471,https://www.pfizer.com//news/press-release/press-release-detail/arvinas-and-pfizer-announce-global-collaboration-develop-1
186,2021-07-22,330.0,134.0,0.42241379219307373,0.25849582158301065,Medicines,Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471,https://www.pfizer.com//news/press-release/press-release-detail/arvinas-and-pfizer-announce-global-collaboration-develop
187,2021-07-21,316.0,149.0,0.3591397841738929,0.2561983469662819,Medicines,Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-provides-update-us-fda-review-abrocitinib-and
188,2021-07-21,349.0,94.0,0.575620766194987,0.2490163011528857,Partnerships,Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-collaboration-biovac
189,2021-07-19,210.0,87.0,0.4141414127469986,0.2690217388867556,Research,Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-complete-recruitment-phase-2-trial-lyme
190,2021-07-19,97.0,11.0,0.7962962889231825,0.269326682620133,Finance,Pfizer Announces New Investor Relations Leader,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-new-investor-relations-leader
191,2021-07-08,276.0,54.0,0.6727272706887052,0.2897278311767095,Partnerships,"Collaboration Between Abbvie, Biogen And Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants To Human Health And Disease.",https://www.pfizer.com//news/press-release/press-release-detail/collaboration-between-abbvie-biogen-and-pfizer-creates-1
192,2021-07-08,278.0,54.0,0.6746987931484976,0.2907180382743274,Partnerships,"Collaboration Between Abbvie, Biogen and Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease",https://www.pfizer.com//news/press-release/press-release-detail/collaboration-between-abbvie-biogen-and-pfizer-creates-0
193,2021-06-30,152.0,49.0,0.5124378083958318,0.25605095508783315,Partnerships,Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206,https://www.pfizer.com//news/press-release/press-release-detail/spero-therapeutics-announces-40-million-equity-investment
194,2021-06-24,46.0,4.0,0.8399999832000004,0.3067484643757763,Finance,Pfizer Declares Third-Quarter 2021 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-third-quarter-2021-dividend
195,2021-06-23,183.0,85.0,0.3656716404265984,0.26274509778162247,Medicines,First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC),https://www.pfizer.com//news/press-release/press-release-detail/first-participant-dosed-pfizers-pivotal-phase-3-talapro-3
196,2021-06-16,418.0,184.0,0.38870431829118884,0.2788327928305545,Research,Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia,https://www.pfizer.com//news/press-release/press-release-detail/data-published-new-england-journal-medicine-shows-pfizers
197,2021-06-16,93.0,10.0,0.8058252348949007,0.2682291659681532,Finance,Pfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-july
198,2021-06-10,389.0,96.0,0.6041237100945903,0.2555321389591506,COVID-19,Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-500-million-doses-covid-19
199,2021-06-08,266.0,88.0,0.5028248573366529,0.23076923061879448,Vaccines,"U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older",https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-prevnar-20tm-pfizers-pneumococcal-20-valent
200,2021-05-28,323.0,95.0,0.5454545441496302,0.2565991404195217,COVID-19,Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-first-authorization-european
201,2021-05-26,334.0,132.0,0.43347639391957854,0.2487987185003744,Medicines,"Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids",https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-receive-fda-approval-myfembreer
202,2021-05-24,287.0,114.0,0.43142144530817594,0.22464985981812333,Research,Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-study-exploring-coadministration-its-20
203,2021-05-20,320.0,91.0,0.5571776142161129,0.25137614663524394,COVID-19,Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY®,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-18-billion
204,2021-05-10,329.0,96.0,0.5482352928276817,0.24781341093421957,COVID-19,Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-first-us-authorization
205,2021-05-07,327.0,87.0,0.5797101435272702,0.2538320047493366,COVID-19,Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID 19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-biologics
206,2021-05-06,376.0,82.0,0.6419213959783375,0.27490996382058225,COVID-19,Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-covid-19-vaccine-doses-olympic
207,2021-05-04,,,,,Finance,PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-strong-first-quarter-2021-results
208,2021-04-28,86.0,9.0,0.8105263072576179,0.27142857065306125,Finance,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-7
209,2021-04-28,172.0,66.0,0.4453781493891674,0.2905982902434697,Partnerships,Pfizer Acquires Amplyx Pharmaceuticals,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquires-amplyx-pharmaceuticals-0
210,2021-04-28,172.0,68.0,0.4333333315277778,0.2912621355688566,Finance,Pfizer Acquires Amplyx Pharmaceuticals,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-acquires-amplyx-pharmaceuticals
211,2021-04-22,84.0,11.0,0.7684210445429364,0.25606468933675286,Finance,Pfizer Declares Second-Quarter 2021 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-second-quarter-2021-dividend
212,2021-04-19,256.0,60.0,0.6202531625941355,0.2567018681911439,COVID-19,Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-100-million-0
213,2021-04-15,133.0,16.0,0.7852348940588262,0.3034623211742112,Finance,Pfizer Invites Shareholders to Attend Virtual-Only 2021 Annual Meeting of Shareholders on April 22,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-shareholders-attend-virtual-only-2021-annual
214,2021-04-12,213.0,59.0,0.5661764685067041,0.24504504482428371,Research,Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-first-participant
215,2021-04-07,296.0,135.0,0.3735498831240142,0.2597950571068143,Medicines,Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-extension-review-new-drug-application
216,2021-04-02,87.0,15.0,0.7058823460207614,0.269841269127404,Finance,"Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-register-webcast-analyst-and-investor
217,2021-04-01,328.0,92.0,0.5619047605668934,0.2405498280409222,COVID-19,Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious
218,2021-03-31,311.0,88.0,0.5588972417070245,0.24167171396627998,Research,Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal
219,2021-03-26,314.0,78.0,0.6020408147907123,0.26326393535039355,Vaccines,"EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union",https://www.pfizer.com//news/press-release/press-release-detail/ema-approves-new-storage-option-pfizer-biontech-vaccine
220,2021-03-25,215.0,66.0,0.5302491084332772,0.308114034749875,Medicines,Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain,https://www.pfizer.com//news/press-release/press-release-detail/joint-fda-advisory-committee-votes-application-tanezumab
221,2021-03-25,104.0,27.0,0.5877862550550668,0.25992063440491936,Research,Results from Pfizer’s Phase 3 Jade Compare Study of Abrocitinib in Moderate to Severe Atopic Dermatitis Published in New England Journal of Medicine,https://www.pfizer.com//news/press-release/press-release-detail/results-pfizers-phase-3-jade-compare-study-abrocitinib
222,2021-03-25,241.0,97.0,0.4260355016981198,0.2543265611329371,Research,"Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer",https://www.pfizer.com//news/press-release/press-release-detail/real-world-evidence-supports-effectiveness-first-line
223,2021-03-24,247.0,89.0,0.4702380938385771,0.23029472225476713,Research,Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-positive-data-phase-3
224,2021-03-23,137.0,32.0,0.6213017714715872,0.24707602303059062,COVID-19,Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-phase-1-study-novel-oral-antiviral
225,2021-03-23,92.0,10.0,0.8039215607458671,0.2756756749306063,Finance,Pfizer Invites Public to View and Listen to Webcast of Pfizer May 4 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-may-4
226,2021-03-11,404.0,129.0,0.5159474661989729,0.25999999987317074,COVID-19,Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared,https://www.pfizer.com//news/press-release/press-release-detail/real-world-evidence-confirms-high-effectiveness-pfizer
227,2021-03-08,205.0,100.0,0.3442622939532384,0.27403414171245805,Research,Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/valneva-and-pfizer-announce-initiation-phase-2-study-lyme
228,2021-03-04,88.0,10.0,0.7959183592253228,0.27071823129635847,Finance,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-6
229,2021-03-03,308.0,135.0,0.3905191864773833,0.25681159405402226,Medicines,U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-expands-approval-pfizers-lorbrenar-first-line
230,2021-02-26,198.0,73.0,0.4612546108440789,0.22985580981352347,Vaccines,European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older,https://www.pfizer.com//news/press-release/press-release-detail/european-medicines-agency-accepts-pfizers-marketing
231,2021-02-26,229.0,76.0,0.5016393426175759,0.2620274911838252,Medicines,EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency,https://www.pfizer.com//news/press-release/press-release-detail/ema-accepts-marketing-application-somatrogon-treat
232,2021-02-25,329.0,103.0,0.523148146937157,0.24927870729989687,COVID-19,Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-part-broad-development
233,2021-02-23,177.0,60.0,0.49367088399294984,0.23605577665731498,Vaccines,U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine),https://www.pfizer.com//news/press-release/press-release-detail/us-fda-accepts-priority-review-pfizers-application
234,2021-02-22,88.0,9.0,0.8144329812945054,0.27094971991354827,Finance,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-5
235,2021-02-19,329.0,78.0,0.6167076151923646,0.24892966345631212,COVID-19,Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-covid-19-vaccine-stability-data
236,2021-02-18,300.0,91.0,0.5345268528528725,0.2512853468822073,Research,Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-commence-global-clinical-trial-evaluate
237,2021-02-17,208.0,71.0,0.49103942476329954,0.22906403922080126,Research,Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-publication-new
238,2021-02-17,181.0,61.0,0.49586776654600095,0.26218851542558125,Research,Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-initiates-pivotal-phase-2-magnetismm-3-trial-bcma
239,2021-02-17,290.0,72.0,0.6022099430878178,0.24659400528161168,Vaccines,Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-200-million
240,2021-02-12,226.0,89.0,0.4349206335399345,0.30172413764202666,Vaccines,U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-panzygar-treatment-adults-chronic
241,2021-02-12,285.0,73.0,0.59217876929559,0.25193525668407085,Vaccines,Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-united-states-100-million
242,2021-02-09,161.0,36.0,0.6345177632765596,0.35178571365752553,Responsibility,Pfizer and IDA Foundation Partner to Expand Access to Essential Cancer Treatments in 70 Low- and Lower-Middle-Income Countries,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-ida-foundation-partner-expand-access-essential
243,2021-02-05,165.0,73.0,0.38655462022456044,0.23587710581181653,Medicines,Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-confirms-us-patent-term-extension-ibrancer
244,2021-02-02,,,,,Finance,PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-fourth-quarter-and-full-year-2020-results
245,2021-01-27,332.0,191.0,0.26959846984780406,0.2628140702196914,Medicines,Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA),https://www.pfizer.com//news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing
246,2021-01-26,218.0,69.0,0.5191637612572692,0.21925133673090041,Research,Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-positive-one-year-data
247,2021-01-25,446.0,194.0,0.3937499993847656,0.24729520855977774,Medicines,European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/european-commission-approves-bavencior-avelumab-first-line
248,2021-01-22,344.0,80.0,0.6226415079654681,0.27622149819138664,COVID-19,Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-reach-agreement-covax-advance-purchase
249,2021-01-14,473.0,205.0,0.3952802354051914,0.28051303256908855,Medicines,Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults,https://www.pfizer.com//news/press-release/press-release-detail/pfizers-xalkorir-crizotinib-approved-fda-alk-positive
250,2021-01-12,127.0,18.0,0.7517241327467301,0.24086378697530933,Partnerships,Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invests-120-million-biotechnology-innovation-through
251,2021-01-10,100.0,13.0,0.7699114976114027,0.21941747530210198,Partnerships,Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to FurtherDevelop CodexDNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and  Development ofmRNA-based Vaccines and Biotherapies,https://www.pfizer.com//news/press-release/press-release-detail/codex-dna-signs-early-access-collaboration-and-licensing
252,2021-01-07,161.0,63.0,0.437499998046875,0.28070175403420833,Research,Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-doses-first-participant-phase-3-study-duchenne
253,2021-01-05,79.0,10.0,0.7752808901653833,0.24585635291199903,Finance,Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-two-webcasts-pfizer
254,2021-01-04,306.0,130.0,0.4036697238447942,0.2698019800310631,Research,US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-accepts-regulatory-submission-pfizer-and-opko-review
255,2020-12-29,281.0,72.0,0.5920679869913088,0.2530465948006834,COVID-19,Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-100-million
256,2020-12-28,416.0,165.0,0.43201376861959767,0.25437828360141057,Medicines,LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA,https://www.pfizer.com//news/press-release/press-release-detail/lorbrenar-lorlatinib-snda-previously-untreated-alk-positive
257,2020-12-28,285.0,86.0,0.5363881387159349,0.2553337919784351,Medicines,Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health,https://www.pfizer.com//news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-collaboration-develop
258,2020-12-23,293.0,72.0,0.6054794503959467,0.2525951555345362,COVID-19,Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-us-100-million-additional-doses
259,2020-12-22,88.0,10.0,0.7959183592253228,0.26203208486087676,Finance,Pfizer Invites Public to View and Listen to Webcast of February 2 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-february-2
260,2020-12-21,432.0,112.0,0.5882352930363322,0.2559999998795294,COVID-19,Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-authorization-european-union
261,2020-12-21,298.0,86.0,0.5520833318956163,0.2648275860242568,COVID-19,Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-chmp-positive-opinion-their
262,2020-12-14,322.0,86.0,0.5784313711312956,0.2523191093059251,COVID-19,Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-provide-data-german-phase-12-study
263,2020-12-12,279.0,73.0,0.5852272710646953,0.23945578215003005,COVID-19,U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/us-cdc-committee-independent-health-experts-recommends
264,2020-12-11,383.0,111.0,0.550607286334803,0.25165562901087335,Vaccines,Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-celebrate-historic-first-authorization
265,2020-12-11,373.0,172.0,0.36880733877283056,0.24874486524475362,Medicines,BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/bavencior-avelumab-receives-positive-chmp-opinion-first-0
266,2020-12-11,376.0,173.0,0.3697632051552583,0.25160403288194133,Medicines,BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/bavencior-avelumab-receives-positive-chmp-opinion-first
267,2020-12-11,114.0,15.0,0.7674418545159546,0.2721518981600171,Finance,Pfizer Declares First-Quarter 2021 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-first-quarter-2021-dividend
268,2020-12-10,260.0,81.0,0.5249266846776344,0.2695652171782093,COVID-19,Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-receive-fda-advisory-committee-vote
269,2020-12-10,278.0,88.0,0.5191256816417331,0.2579281182114671,Research,Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-publication-results-landmark
270,2020-12-08,206.0,74.0,0.471428569744898,0.21655065721844494,Vaccines,U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-accepts-priority-review-biologics-license
271,2020-12-07,177.0,49.0,0.5663716789098598,0.27935723080425556,Research,Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-positive-clinical-data-bcma-cd3-bispecific
272,2020-12-07,264.0,73.0,0.5667655769532178,0.2610379548713881,Research,Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10¹³ VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-sangamo-announce-updated-phase-12-results-0
273,2020-12-02,315.0,86.0,0.5710723177778745,0.2536369384859981,COVID-19,Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-achieve-first-authorization-world
274,2020-11-23,150.0,55.0,0.4634146318857823,0.24848484818365474,Research,"Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-doses-first-participant-phase-3-study-evaluating
275,2020-11-20,297.0,78.0,0.5839999984426667,0.260235947078254,COVID-19,Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization
276,2020-11-19,127.0,14.0,0.8014184340324934,0.33975903532588186,Partnerships,Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-lianbio-announce-strategic-collaboration-expand
277,2020-11-19,405.0,165.0,0.42105263084025857,0.25583482932861995,Research,Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine,https://www.pfizer.com//news/press-release/press-release-detail/results-phase-3-crown-trial-pfizers-lorbrenar-lorlatinib
278,2020-11-18,275.0,77.0,0.5624999984019886,0.25618631713523554,COVID-19,"Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine
279,2020-11-16,109.0,12.0,0.801652885936753,0.24151696558579447,Finance,Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-transaction-combine-its-upjohn-business
280,2020-11-12,264.0,70.0,0.5808383216142565,0.26114151660583146,Medicines,Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg,https://www.pfizer.com//news/press-release/press-release-detail/analysis-phase-3-attr-act-and-its-long-term-extension-study
281,2020-11-11,82.0,9.0,0.8021977933824419,0.2570621461664911,Finance,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-4
282,2020-11-11,243.0,88.0,0.46827794420459834,0.24428044262414725,Research,"Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimens",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-results-fifth-phase-3-trial
283,2020-11-11,317.0,68.0,0.6467532450733682,0.2524590162278957,COVID-19,Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-reach-agreement-supply-eu-200-million
284,2020-11-09,159.0,56.0,0.479069765213629,0.2901484476516215,Partnerships,Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/homology-medicines-announces-60-million-equity-investment
285,2020-11-09,311.0,79.0,0.5948717933464825,0.2793696273070418,Research,Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against
286,2020-11-06,386.0,199.0,0.3196581191116955,0.2700831023683827,Medicines,Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS),https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-phase-3-study-results-xeljanz-r
287,2020-11-05,246.0,36.0,0.7446808484231175,0.2452173910911153,Finance,Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-details-when-issued-and-ex-distribution
288,2020-10-30,305.0,45.0,0.7428571407346939,0.2669717770656203,Finance,Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn,https://www.pfizer.com//news/press-release/press-release-detail/mylan-and-pfizer-receive-clearance-us-federal-trade
289,2020-10-27,204.0,50.0,0.6062992102114204,0.23962264128337485,Research,"FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis",https://www.pfizer.com//news/press-release/press-release-detail/fda-grants-priority-review-and-ema-accepts-regulatory
290,2020-10-27,,,,,Finance,PFIZER REPORTS THIRD-QUARTER 2020 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-third-quarter-2020-results
291,2020-10-21,263.0,119.0,0.37696334979852525,0.2070460703484845,Research,Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020,https://www.pfizer.com//news/press-release/press-release-detail/data-pfizers-adult-and-pediatric-clinical-trial-programs-20
292,2020-10-09,221.0,105.0,0.3558282197673981,0.2407680943568921,Medicines,PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint,https://www.pfizer.com//news/press-release/press-release-detail/penelope-b-trial-ibrancer-palbociclib-early-breast-cancer
293,2020-10-08,278.0,126.0,0.376237622831095,0.273898304899052,Research,Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-phase-3-top-line-results-once
294,2020-10-07,254.0,63.0,0.6025236574052881,0.2622001652090983,Research,Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-sangamo-dose-first-participant-phase-3-study
295,2020-10-06,230.0,56.0,0.6083916062643651,0.2672897193763647,COVID-19,BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2,https://www.pfizer.com//news/press-release/press-release-detail/biontech-and-pfizer-initiate-rolling-submission-european
296,2020-10-05,137.0,45.0,0.5054945027170632,0.23423423393277448,Partnerships,SpringWorks Therapeutics Announces Clinical Collaboration with PfizerInc. to  Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed  or Refractory Multiple Myeloma,https://www.pfizer.com//news/press-release/press-release-detail/springworks-therapeutics-announces-clinical-collaboration
297,2020-10-01,145.0,44.0,0.5343915315640659,0.28124999958147323,Research,Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-fda-fast-track-designation-duchenne
298,2020-09-28,388.0,166.0,0.4007220209373249,0.2515894640092691,Medicines,U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment
299,2020-09-24,46.0,4.0,0.8399999832000004,0.30487804692147535,Finance,Pfizer Declares Fourth-Quarter 2020 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2020-dividend
300,2020-09-23,139.0,35.0,0.5977011459902233,0.2664624804495215,Partnerships,Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s  Investigational Gene Therapy for Wilson Disease,https://www.pfizer.com//news/press-release/press-release-detail/vivet-therapeutics-and-pfizer-inc-enter-manufacturing
301,2020-09-23,283.0,129.0,0.37378640685974174,0.264951768318359,Medicines,FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma,https://www.pfizer.com//news/press-release/press-release-detail/fda-accepts-supplemental-new-drug-application-pfizers
302,2020-09-22,88.0,10.0,0.7959183592253228,0.2585751972069256,Finance,Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-october-27
303,2020-09-22,88.0,13.0,0.7425742500735223,0.23990498755366987,Partnerships,Javelin Biotech Aims to Develop Industry-Leading “Organ-on-a-Chip” Predictive  Pharmacokinetics Platform in Collaboration with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/javelin-biotech-aims-develop-industry-leading-organ-chip
304,2020-09-18,417.0,188.0,0.37851239606857456,0.23790798260404722,Research,BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine,https://www.pfizer.com//news/press-release/press-release-detail/bavencio-pivotal-phase-iii-javelin-bladder-100-results
305,2020-09-15,331.0,99.0,0.539534882466198,0.22107969140304384,COVID-19,Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-investor-day-features-significant-number-pipeline
306,2020-09-14,92.0,20.0,0.642857137117347,0.20856610761905753,Finance,Pfizer Hosts Virtual Investor Day,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-hosts-virtual-investor-day
307,2020-09-12,164.0,41.0,0.5999999970731708,0.2575376881186712,COVID-19,Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-propose-expansion-pivotal-covid-19
308,2020-09-11,82.0,10.0,0.7826086871455578,0.255555554845679,Finance,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-3
309,2020-09-10,190.0,35.0,0.6888888858271606,0.26071842379986276,Research,Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 2020,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-present-latest-scientific-advancements-its-industry
310,2020-09-09,234.0,72.0,0.5294117629757785,0.23556581968008788,COVID-19,Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-data-preclinical-studies-mrna
311,2020-09-09,263.0,53.0,0.6645569599222881,0.2577487762987367,COVID-19,Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-potentially-supply-eu-200-million-doses
312,2020-09-08,565.0,125.0,0.6376811584961143,0.29175475674767243,Vaccines,Biopharma Leaders Unite To Stand With Science,https://www.pfizer.com//news/press-release/press-release-detail/biopharma-leaders-unite-stand-science
313,2020-09-03,94.0,13.0,0.7570093387195389,0.25598086063162473,Finance,"Pfizer Invites Public to Register for Webcast of Virtual Investor Day on September 14 and 15, 2020",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-register-webcast-virtual-investor-day
314,2020-08-20,283.0,72.0,0.5943661955088276,0.2361942779532972,COVID-19,Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-share-positive-early-data-lead-mrna
315,2020-08-07,101.0,14.0,0.756521732551985,0.2832512308294305,COVID-19,Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-agreement-gilead-manufacture-remdesivir
316,2020-08-06,89.0,10.0,0.7979797899193961,0.24205378913923278,Finance,"Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-times-rescheduled-virtual-investor-day
317,2020-08-05,394.0,165.0,0.4096601066016814,0.26182669776963624,Medicines,LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/lorbrenar-lorlatinib-significantly-improves-progression
318,2020-08-05,234.0,49.0,0.6537102450398932,0.25518485098720933,Vaccines,Pfizer and BioNTech to Supply Canada with their BNT162 mRNA- Based Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-canada-their-bnt162-mrna-based
319,2020-07-31,240.0,55.0,0.6271186419419708,0.25945470513680324,COVID-19,Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-supply-japan-120-million-doses-their
320,2020-07-28,,,,,Finance,Pfizer Reports Second-Quarter 2020 Results,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-second-quarter-2020-results
321,2020-07-27,291.0,90.0,0.5275590537334408,0.24983606540994355,Research,Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate
322,2020-07-22,279.0,58.0,0.6557863482024144,0.27398373961464734,Vaccines,Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-agreement-us-government-600
323,2020-07-20,250.0,70.0,0.5624999982421875,0.23952095790455016,Research,"Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-update-german
324,2020-07-20,260.0,50.0,0.677419352653486,0.2667814111301365,Vaccines,Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-agreement-united-kingdom-30
325,2020-07-13,190.0,42.0,0.6379310317330559,0.23269809404945024,Vaccines,Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-granted-fda-fast-track-designation-two
326,2020-07-09,133.0,41.0,0.5287356291451976,0.2989690716512559,Finance,Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-pledges-100-million-new-industry-fund-help-fight
327,2020-07-01,252.0,70.0,0.5652173895490143,0.22676056322059113,Research,Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-data-ongoing
328,2020-06-30,473.0,195.0,0.4161676640476532,0.258914728581816,Medicines,FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/fda-approves-bavencio-first-line-maintenance-treatment
329,2020-06-30,209.0,62.0,0.5424354223526369,0.24771480781744531,Medicines,European Commission Approves DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML),https://www.pfizer.com//news/press-release/press-release-detail/european-commission-approves-daurismotm-glasdegib-certain
330,2020-06-25,44.0,4.0,0.8333333159722226,0.29813664411095253,Finance,Pfizer Declares Third-Quarter 2020 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-declares-third-quarter-2020-dividend
331,2020-06-24,211.0,71.0,0.49645389894874503,0.29497907918935246,Responsibility,Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-wellcome-launch-surveillance-program-combat
332,2020-06-22,312.0,136.0,0.3928571419802296,0.2412493267413843,Medicines,European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/european-medicines-agency-validates-application-bavencior
333,2020-06-22,233.0,121.0,0.31638417989721984,0.2439696759173193,Research,Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-start-four-phase-3-clinical-trials
334,2020-06-22,214.0,64.0,0.5395683433828476,0.25622119792053344,Research,European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/european-medicines-agency-validates-application-bavencior-0
335,2020-06-18,241.0,59.0,0.6066666646444444,0.24370430524475684,Research,Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-sangamo-announce-updated-phase-12-results
336,2020-06-18,359.0,53.0,0.7427184447992271,0.2630906767157786,Finance,Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn,https://www.pfizer.com//news/press-release/press-release-detail/upjohn-announces-pricing-senior-notes-connection-proposed
337,2020-06-16,93.0,10.0,0.8058252348949007,0.25245097977340447,Finance,Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-july-28
338,2020-06-12,75.0,9.0,0.7857142763605444,0.252252251494738,Finance,Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-june-18
339,2020-06-11,255.0,72.0,0.5596330258115199,0.3111322546992081,Medicines,"FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)",https://www.pfizer.com//news/press-release/press-release-detail/fda-approves-pfizers-oncology-supportive-care-biosimilar
340,2020-06-10,196.0,63.0,0.5135135115308359,0.2322869953073659,Research,Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-jade-teen-trial
341,2020-06-03,224.0,76.0,0.4933333316888889,0.23980815328552504,Research,Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology,https://www.pfizer.com//news/press-release/press-release-detail/complete-results-second-pivotal-monotherapy-study
342,2020-06-02,133.0,15.0,0.7972972919101534,0.23756019223505587,Finance,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-2
343,2020-05-29,237.0,109.0,0.3699421954625948,0.25516224169973284,Medicines,"Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-provides-update-phase-3-pallas-trial-ibrancer
344,2020-05-29,240.0,123.0,0.3223140486988594,0.24560216492178472,Medicines,Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/final-prosper-results-show-xtandir-enzalutamide
345,2020-05-22,114.0,11.0,0.8239999934080001,0.31645569540137797,Finance,"Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-inc-recommends-rejection-unsolicited-note-tender
346,2020-05-18,116.0,14.0,0.7846153785798817,0.30732860447440047,Finance,"Pfizer Prices $4,000,000,000 Debt Offering",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-prices-4000000000-debt-offering
347,2020-05-15,272.0,84.0,0.5280898861570509,0.27661227639734864,Research,Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study,https://www.pfizer.com//news/press-release/press-release-detail/pfizers-new-phase-1b-results-gene-therapy-ambulatory-boys
348,2020-05-14,221.0,91.0,0.41666666533119656,0.2255965291210437,Research,Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-lot
349,2020-05-13,88.0,10.0,0.7959183592253228,0.2585751972069256,Finance,"Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day",https://www.pfizer.com//news/press-release/press-release-detail/save-date-pfizer-announces-new-date-september-14-2020
350,2020-05-12,186.0,42.0,0.631578944598338,0.24385026711887672,Research,New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program,https://www.pfizer.com//news/press-release/press-release-detail/new-data-18-approved-and-investigational-pfizer-medicines
351,2020-05-12,134.0,14.0,0.8108108053323594,0.23756019223505587,Finance,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-1
352,2020-05-08,71.0,7.0,0.8205128099934256,0.24920127715910134,Research,Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-may-15
353,2020-05-05,208.0,45.0,0.6442687721570405,0.24999999975296444,Research,Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_biontech_dose_first_participants_in_the_u_s_as_part_of_global_covid_19_mrna_vaccine_development_program
354,2020-05-04,204.0,113.0,0.2870662451512106,0.299056603491456,Research,New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized,https://www.pfizer.com//news/press-release/press-release-detail/new-data-suggest-burden-group-b-streptococcus-gbs-infection
355,2020-04-30,207.0,79.0,0.4475524459875789,0.28288822919595624,Partnerships,"Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15",https://www.pfizer.com//news/press-release/press-release-detail/valneva_and_pfizer_announce_collaboration_to_co_develop_and_commercialize_lyme_disease_vaccine_vla15
356,2020-04-30,85.0,13.0,0.7346938700541442,0.30061349601038806,Partnerships,AMRA Medical renews collaboration with Pfizer Inc.  aiming to generate the world’s  largest imaging dataset on body  composition profiling,https://www.pfizer.com//news/press-release/press-release-detail/amra-medical-renews-collaboration-pfizer-inc-aiming
357,2020-04-29,160.0,38.0,0.6161616130496889,0.2605263154466759,Research,BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany,https://www.pfizer.com//news/press-release/press-release-detail/biontech-and-pfizer-announce-completion-dosing-first-cohort
358,2020-04-28,1379.0,487.0,0.47802786683921333,0.2778025904008035,Finance,PFIZER REPORTS FIRST-QUARTER 2020 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-first-quarter-2020-results
359,2020-04-23,99.0,15.0,0.7368420987996307,0.26267281045467095,Finance,Pfizer Hosts Virtual-Only Annual Meeting of Shareholders,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-hosts-virtual-only-annual-meeting-shareholders
360,2020-04-22,118.0,34.0,0.5526315753116344,0.24516128992715921,Partnerships,FoRx Therapeutics AG Raises EUR 10 Million Seed Round to Develop a Pipeline  of Drugs Targeting DNA Replication Stress for Cancer,https://www.pfizer.com//news/press-release/press-release-detail/forx-therapeutics-ag-raises-eur-10-million-seed-round
361,2020-04-22,195.0,45.0,0.6249999973958333,0.24819027895740406,Research,BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates,https://www.pfizer.com//news/press-release/press-release-detail/biontech_and_pfizer_announce_regulatory_approval_from_german_authority_paul_ehrlich_institut_to_commence_first_clinical_trial_of_covid_19_vaccine_candidates
362,2020-04-20,147.0,63.0,0.3999999980952381,0.2837837834002922,Partnerships,Valneva Receives FDA Fast Track Designation for its Lyme Disease  Vaccine Candidate VLA15,https://www.pfizer.com//news/press-release/press-release-detail/valneva-receives-fda-fast-track-designation-its-lyme
363,2020-04-09,223.0,69.0,0.5273972584678176,0.2917082914168748,COVID-19,Pfizer Advances Battle Against COVID-19 on Multiple Fronts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-advances-battle-against-covid-19-multiple-fronts
364,2020-04-09,209.0,40.0,0.6787148567119885,0.2538226297106803,COVID-19,Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-announce-further-details-collaboration
365,2020-04-08,286.0,108.0,0.45177664859955163,0.2372065019643549,Medicines,U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy,https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-braftovir-encorafenib-combination-cetuximab
366,2020-04-07,55.0,7.0,0.7741935359001043,0.2731277521007588,Finance,Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-hold-virtual-only-2020-annual-meeting-shareholders
367,2020-04-06,256.0,48.0,0.684210524065097,0.3739237387774616,Responsibility,"Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-pfizer-foundation-donate-40-million-charitable
368,2020-04-02,235.0,102.0,0.3946587525381046,0.2905172411288644,Medicines,"Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-european-approval-oncology-biosimilar
369,2020-04-02,62.0,12.0,0.6756756665449235,0.2542955317721803,Leadership,Susan Desmond-Hellmann Elected to Pfizer’s Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/susan-desmond-hellmann-elected-pfizers-board-directors
370,2020-04-01,303.0,76.0,0.598944589448695,0.36026615935335915,COVID-19,"Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic",https://www.pfizer.com//news/press-release/press-release-detail/medical-professionals-across-merck-co-inc-pfizer-inc-and
371,2020-03-27,157.0,23.0,0.744444440308642,0.2922077917334289,Responsibility,Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-completes-125-billion-sustainability-bond-social-and
372,2020-03-26,314.0,49.0,0.7300275461982713,0.2792307690159763,Finance,Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn,https://www.pfizer.com//news/press-release/press-release-detail/mylan-and-pfizer-provide-update-regarding-proposed
373,2020-03-24,220.0,41.0,0.6858237521615949,0.2727272724422913,Medicines,"U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis",https://www.pfizer.com//news/press-release/press-release-detail/us-fda-approves-supplemental-new-drug-application-snda
374,2020-03-18,232.0,97.0,0.4103343452573424,0.22139973067200555,Research,Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-top-line-results-phase-3-study-20-valent
375,2020-03-18,198.0,56.0,0.5590551159092318,0.21273031807979034,Research,"Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-third-phase-3
376,2020-03-18,49.0,6.0,0.781818167603306,0.34591194750998777,Finance,"Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_postpones_investor_day_scheduled_for_march_31_2020_due_to_coronavirus_concerns
377,2020-03-18,198.0,58.0,0.5468749978637696,0.21713316351388195,Research,"Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_third_phase_3_trial_of_abrocitinib_for_moderate_to_severe_atopic_dermatitis_which_showed_improvements_in_skin_clearance_disease_extent_and_severity_and_itch
378,2020-03-17,91.0,10.0,0.8019801900794041,0.2556962018843134,Finance,Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-april-28
379,2020-03-17,184.0,41.0,0.6355555527308642,0.2637749117657973,COVID-19,Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-co-develop-potential-covid-19-vaccine-0
380,2020-03-17,187.0,42.0,0.6331877701607521,0.25963718791424356,COVID-19,Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-and-biontech-co-develop-potential-covid-19-vaccine
381,2020-03-13,163.0,37.0,0.6299999968500001,0.3067484657871956,COVID-19,Pfizer Outlines Five-Point Plan to Battle COVID-19,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-outlines-five-point-plan-battle-covid-19
382,2020-03-13,330.0,149.0,0.3778705628854477,0.24426313093102336,Research,EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study,https://www.pfizer.com//news/press-release/press-release-detail/emd_serono_and_pfizer_provide_update_on_phase_iii_javelin_head_and_neck_100_study
383,2020-03-04,62.0,10.0,0.7222222121913582,0.25806451520406987,Leadership,Susan Hockfield Elected to Pfizer’s Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/susan-hockfield-elected-pfizers-board-directors
384,2020-03-02,188.0,49.0,0.586497887820684,0.30580645121831423,Medicines,"U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis",https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_accepts_regulatory_submission_for_tanezumab_a_potential_first_in_class_treatment_for_patients_with_chronic_pain_due_to_moderate_to_severe_osteoarthritis
385,2020-02-27,64.0,10.0,0.7297297198685173,0.29019607729334873,Leadership,James Quincey Elected to Pfizer’s Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/james-quincey-elected-pfizers-board-directors
386,2020-02-27,379.0,53.0,0.7546296278828017,0.27639155452566116,Finance,Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer,https://www.pfizer.com//news/press-release/press-release-detail/mylan-and-pfizer-announce-appointment-viatris-chief
387,2020-02-27,479.0,152.0,0.5182250387983756,0.26816829567863654,Finance,Mylan and Pfizer Finalize Appointments to Viatris Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/mylan-and-pfizer-finalize-appointments-viatris-board
388,2020-02-27,376.0,52.0,0.7570093440256791,0.2793733679638555,Finance,Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer,https://www.pfizer.com//news/press-release/press-release-detail/mylan_and_pfizer_announce_appointment_of_viatris_chief_financial_officer
389,2020-02-27,477.0,151.0,0.5191082794281715,0.27034007736963406,Finance,Mylan and Pfizer Finalize Appointments to Viatris Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/mylan_and_pfizer_finalize_appointments_to_viatris_board_of_directors
390,2020-02-25,142.0,14.0,0.820512815253123,0.2403697993214641,Finance,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_listen_to_webcast_of_pfizer_discussion_at_healthcare_conference-26
391,2020-02-20,64.0,15.0,0.6202531567056563,0.22128851478630668,Partnerships,"Montis Biosciences launched with €8,4 million seed financing and a novel  approach to immune-oncology",https://www.pfizer.com//news/press-release/press-release-detail/montis-biosciences-launched-eu84-million-seed-financing-and
392,2020-02-18,233.0,66.0,0.5585284262256575,0.2575366061519926,Medicines,"European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)",https://www.pfizer.com//news/press-release/press-release-detail/european-commission-approves-vyndaqelr-first-treatment-eu
393,2020-02-11,241.0,108.0,0.38108882412295464,0.2589020769592714,Research,XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC,https://www.pfizer.com//news/press-release/press-release-detail/xtandir-enzalutamide-demonstrates-significant-improvement
394,2020-01-31,166.0,35.0,0.6517412902898443,0.30134932488553323,Medicines,"Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)",https://www.pfizer.com//news/press-release/press-release-detail/pfizer-receives-positive-chmp-opinion-oncology-biosimilar
395,2020-01-28,1097.0,409.0,0.45683930912560466,0.2637478108119531,Finance,PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-reports-fourth-quarter-and-full-year-2019-results
396,2020-01-23,160.0,41.0,0.5920397980495532,0.32419354786420396,Vaccines,Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-vaccines-launches-global-centers-excellence-network
397,2020-01-23,288.0,58.0,0.66473988247185,0.3075555552821728,Medicines,Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate),https://www.pfizer.com//news/press-release/press-release-detail/pfizers-greenstone-and-digital-mens-health-clinic-roman
398,2020-01-14,41.0,6.0,0.7446808352195567,0.25543478122046315,Partnerships,Insilico enters into research collaboration with Pfizer Inc. to explore novel data  and artificial intelligence system for potential therapeutic targets,https://www.pfizer.com//news/press-release/press-release-detail/insilico-enters-research-collaboration-pfizer-inc-explore
399,2020-01-13,93.0,61.0,0.20779220644290775,0.24600638938337638,Partnerships,Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease  and Parkinson’s Disease from Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/biogen-acquire-novel-clinical-stage-asset-application
400,2020-01-13,241.0,145.0,0.24870466256812263,0.2964669736586275,Partnerships,Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine  Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate,https://www.pfizer.com//news/press-release/press-release-detail/axsome-therapeutics-enters-exclusive-license-agreement
401,2020-01-07,142.0,15.0,0.8089171922998905,0.24079754564294856,Finance,Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-0
402,2020-01-06,406.0,176.0,0.3951890027574072,0.2580931262713556,Research,BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/bavencio-significantly-improved-overall-survival-patients
403,2019-12-23,246.0,57.0,0.623762374179002,0.29106628214114666,Partnerships,"Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program",https://www.pfizer.com//news/press-release/press-release-detail/theravance_biopharma_and_pfizer_inc_enter_global_license_agreement_for_skin_targeted_locally_acting_pan_janus_kinase_jak_inhibitor_program
404,2019-12-23,68.0,8.0,0.7894736738227148,0.2310030388115409,Partnerships,BioInvent announces selection of second target and extension of the research  collaboration and license agreement with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/bioinvent-announces-selection-second-target-and-extension
405,2019-12-18,309.0,112.0,0.46793349057497985,0.22477309117737687,Medicines,U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_accepts_and_grants_priority_review_to_snda_for_braftovi_encorafenib_in_combination_with_erbitux_cetuximab_braftovi_doublet_for_the_treatment_of_brafv600e_mutant_metastatic_colorectal_cancer_after_prior
406,2019-12-18,301.0,57.0,0.6815642439062451,0.2827804105191308,Finance,Pfizer and Mylan Announce Two Future Viatris Board Members,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_mylan_announce_two_future_viatris_board_members
407,2019-12-17,87.0,7.0,0.8510638207333636,0.2611111103858025,Finance,Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_january_28_conference_call_with_analysts-0
408,2019-12-17,121.0,48.0,0.4319526601659606,0.23702664763390371,Partnerships,Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of  Transformative Treatments for Triplet Repeat Disorders,https://www.pfizer.com//news/press-release/press-release-detail/triplet-therapeutics-launches-59-million-financing-further
409,2019-12-16,312.0,144.0,0.36842105182363805,0.27669902895831366,Medicines,XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/xtandi_enzalutamide_approved_by_u_s_fda_for_the_treatment_of_metastatic_castration_sensitive_prostate_cancer
410,2019-12-16,156.0,20.0,0.7727272683367769,0.27160493785246154,Finance,Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_first_quarter_2020_dividend_and_announces_upcoming_investor_day_to_highlight_strength_of_innovative_r_d_pipeline
411,2019-12-13,227.0,77.0,0.4934210510084834,0.258723404035129,Medicines,"Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_vyndaqel_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease
412,2019-12-12,333.0,149.0,0.38174273779721424,0.2695749439208194,Medicines,FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis,https://www.pfizer.com//news/press-release/press-release-detail/fda_approves_xeljanz_xr_tofacitinib_extended_release_tablets_for_the_treatment_of_ulcerative_colitis
413,2019-12-10,81.0,18.0,0.6363636299357209,0.2749999992361111,Partnerships,"ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and  BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials",https://www.pfizer.com//news/press-release/press-release-detail/immunos-therapeutics-ag-raises-chf-15m-series-financing-co
414,2019-12-07,349.0,110.0,0.5206971666215748,0.23868954745777973,Research,Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer,https://www.pfizer.com//news/press-release/press-release-detail/findings_released_from_real_world_data_analysis_of_eliquis_apixaban_for_the_treatment_of_venous_thromboembolism_in_patients_with_active_cancer
415,2019-12-07,280.0,58.0,0.6568047317846014,0.26889419230796,Research,Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment,https://www.pfizer.com//news/press-release/press-release-detail/sangamo_and_pfizer_announce_updated_phase_1_2_results_showing_sustained_increased_factor_viii_activity_through_44_weeks_following_sb_525_gene_therapy_treatment
416,2019-12-04,79.0,23.0,0.5490196024605921,0.20278329979565946,Partnerships,ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel  Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases,https://www.pfizer.com//news/press-release/press-release-detail/imcheck-raises-53-million-series-b-advance-clinical
417,2019-11-22,49.0,10.0,0.6610169379488655,0.22014925290989085,Partnerships,CeMM enters into research collaboration on expanding the druggable proteome  with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/cemm-enters-research-collaboration-expanding-druggable
418,2019-11-18,287.0,117.0,0.4207920781663562,0.2887776981495513,Medicines,"FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions",https://www.pfizer.com//news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_abrilada_adalimumab_afzb_for_multiple_inflammatory_conditions
419,2019-11-15,209.0,53.0,0.5954198450556495,0.2643794144658129,Research,"Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals",https://www.pfizer.com//news/press-release/press-release-detail/bristol_myers_squibb_and_pfizer_announce_randomized_controlled_trial_to_evaluate_the_effect_of_atrial_fibrillation_screening_on_health_outcomes_in_older_individuals
420,2019-11-13,76.0,21.0,0.5670103034328835,0.3265993254996656,Partnerships,CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/centogene-signs-data-access-and-collaboration-agreement
421,2019-11-12,325.0,48.0,0.742627343853546,0.2981614705850028,Finance,Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination,https://www.pfizer.com//news/press-release/press-release-detail/mylan_and_pfizer_announce_viatris_as_the_new_company_name_in_the_planned_mylan_upjohn_combination
422,2019-11-12,317.0,173.0,0.29387755042065805,0.25925925912208503,Research,Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_results_of_phase_3_study_for_xeljanz_tofacitinib_in_juvenile_idiopathic_arthritis_ahead_of_presentation_at_2019_american_college_of_rheumatology_association_of_rheumatology_professionals_annual
423,2019-11-08,356.0,163.0,0.3718689780888844,0.25453653739355736,Research,EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial,https://www.pfizer.com//news/press-release/press-release-detail/emd_serono_and_pfizer_provide_update_on_phase_iii_javelin_gastric_100_trial
424,2019-10-29,,,,,Finance,PFIZER REPORTS THIRD-QUARTER 2019 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_third_quarter_2019_results
425,2019-10-28,438.0,216.0,0.33944954076536765,0.23508267425050947,Medicines,European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/european_commission_approves_bavencio_avelumab_plus_axitinib_combination_for_first_line_treatment_of_patients_with_advanced_renal_cell_carcinoma
426,2019-10-21,285.0,130.0,0.37349397500362896,0.2730263156098511,Research,"OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency",https://www.pfizer.com//news/press-release/press-release-detail/opko_and_pfizer_announce_positive_phase_3_top_line_results_for_somatrogon_an_investigational_long_acting_human_growth_hormone_to_treat_children_with_growth_hormone_deficiency
427,2019-10-17,284.0,48.0,0.7108433713528814,0.2782900249134199,Partnerships,The Bristol-Myers Squibb-Pfizer Alliance and Fitbit Collaborate to Address Gaps in Atrial Fibrillation Detection with the Aim of Accelerating Diagnosis,https://www.pfizer.com//news/press-release/press-release-detail/the_bristol_myers_squibb_pfizer_alliance_and_fitbit_collaborate_to_address_gaps_in_atrial_fibrillation_detection_with_the_aim_of_accelerating_diagnosis
428,2019-10-14,89.0,16.0,0.6952380886167802,0.24822694976778498,Partnerships,ImaginAb signs multi-party collaboration agreement with three global  pharmaceutical companies to help further develop company’s CD8  ImmunoPET technology,https://www.pfizer.com//news/press-release/press-release-detail/imaginab-signs-multi-party-collaboration-agreement-three
429,2019-10-12,202.0,75.0,0.4584837528574594,0.23634812266523195,Research,Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_positive_phase_3_data_at_the_28th_congress_of_the_european_academy_of_dermatology_and_venereology_for_abrocitinib_in_moderate_to_severe_atopic_dermatitis
430,2019-10-07,186.0,50.0,0.5762711839988509,0.24057084583020302,Partnerships,Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx,https://www.pfizer.com//news/press-release/press-release-detail/akcea_and_pfizer_inc_announce_licensing_agreement_for_investigative_antisense_therapy_akcea_angptl3_lrx
431,2019-09-29,337.0,125.0,0.4588744578812241,0.22658165756420712,Research,"Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_interim_analysis_results_from_phase_3_beacon_crc_trial_of_braftovi_encorafenib_mektovi_binimetinib_and_cetuximab_for_the_treatment_of_brafv600e_mutant_metastatic_colorectal_cancer
432,2019-09-27,136.0,23.0,0.7106918194296112,0.33901918904260303,Leadership,Ian Read to Retire as Executive Chairman of Pfizer’s Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman,https://www.pfizer.com//news/press-release/press-release-detail/ian_read_to_retire_as_executive_chairman_of_pfizer_s_board_of_directors_chief_executive_officer_dr_albert_bourla_named_chairman
433,2019-09-27,196.0,68.0,0.48484848301193756,0.2424242422016306,Research,"Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_second_pivotal_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis
434,2019-09-27,444.0,202.0,0.37461300251607893,0.23195691194543738,Research,New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019,https://www.pfizer.com//news/press-release/press-release-detail/new_data_for_bavencio_avelumab_for_advanced_cancers_to_be_presented_at_esmo_2019
435,2019-09-24,41.0,4.0,0.8222222039506177,0.3214285691326531,Finance,Pfizer Declares Fourth-Quarter 2019 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_fourth_quarter_2019_dividend
436,2019-09-24,261.0,97.0,0.45810055737960736,0.2613138684223986,Medicines,"Pfizer Presents New Evidence of IBRANCE® (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_new_evidence_of_ibrance_palbociclib_effectiveness_in_hr_her2_metastatic_breast_cancer_patients_in_four_real_world_studies_at_esmo_congress_2019
437,2019-09-24,192.0,34.0,0.6991150411543582,0.3419062022058908,Partnerships,Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_flatiron_health_announce_expanded_strategic_collaboration_to_unlock_power_of_real_world_evidence_in_oncology
438,2019-09-20,384.0,184.0,0.35211267543642133,0.23183673459925033,Medicines,CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/chmp_adopts_positive_opinion_for_bavencio_avelumab_plus_axitinib_for_first_line_treatment_of_patients_with_advanced_renal_cell_carcinoma
439,2019-09-19,701.0,375.0,0.30297397741359294,0.2393238433631397,Research,Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_scientific_advancements_in_cancer_care_at_the_esmo_congress_2019_highlighting_expanded_portfolio
440,2019-09-17,16.0,1.0,0.8823528892733594,0.19101123380886253,Finance,Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call With Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_october_29_conference_call_with_analysts-0
441,2019-09-09,202.0,80.0,0.43262411194104927,0.22257300692772453,Research,Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_preliminary_results_from_a_proof_of_concept_phase_2_study_b7471003_of_its_20_valent_pneumococcal_conjugate_vaccine_candidate_being_investigated_for_the_prevention_of_invasive_disease_and
442,2019-08-21,268.0,133.0,0.3366583532751662,0.2650363514441266,Medicines,U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_grants_xtandi_enzalutamide_application_priority_review_for_the_treatment_of_men_with_metastatic_hormone_sensitive_prostate_cancer
443,2019-08-21,119.0,9.0,0.8593749932861329,0.24474187333701364,Finance,"Pfizer Invests Half Billion Dollars to Advance State-of-the-Art Gene Therapy Facility in Sanford, North Carolina",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invests_half_billion_dollars_to_advance_state_of_the_art_gene_therapy_facility_in_sanford_north_carolina
444,2019-08-20,159.0,45.0,0.5588235266724337,0.35478260807863893,Research,The Pfizer Foundation Invests in 20 Organizations Tackling Infectious Diseases and Antimicrobial Resistance,https://www.pfizer.com//news/press-release/press-release-detail/the_pfizer_foundation_invests_in_20_organizations_tackling_infectious_diseases_and_antimicrobial_resistance
445,2019-08-02,198.0,74.0,0.45588235126513843,0.31156930090312795,Research,Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_phase_3_top_line_results_for_rivipansel_in_patients_with_sickle_cell_disease_experiencing_a_vaso_occlusive_crisis
446,2019-08-01,132.0,18.0,0.7599999949333334,0.2538071061695311,Partnerships,Pfizer Announces Closing of Joint Venture With GlaxoSmithKline to Create a Premier Global Consumer Healthcare Company,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_closing_of_joint_venture_with_glaxosmithkline_to_create_a_premier_global_consumer_healthcare_company
447,2019-07-31,55.0,10.0,0.6923076816568049,0.22887323863072803,Partnerships,BioInvent announces selection of first target discovered by BioInvent’s  proprietary F.I.R.S.TTM technology platform under collaboration with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/bioinvent-announces-selection-first-target-discovered
448,2019-07-30,205.0,47.0,0.6269841244960948,0.2683706067429493,Finance,Pfizer Completes Acquisition of Array Biopharma,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_completes_acquisition_of_array_biopharma
449,2019-07-29,10.0,1.0,0.8181817438016598,0.13749999828125004,Finance,"Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call to July 29, 2019 at 10:30 a.m. EDT",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_inc_reschedules_second_quarter_2019_earnings_conference_call_to_july_29_2019_at_10_30_a_m_edt
450,2019-07-29,,,,,Finance,PFIZER REPORTS SECOND-QUARTER 2019 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_second_quarter_2019_results
451,2019-07-29,524.0,99.0,0.6821829844587753,0.2889610388270125,Finance,"Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine",https://www.pfizer.com//news/press-release/press-release-detail/mylan_and_upjohn_a_division_of_pfizer_to_combine_creating_a_new_champion_for_global_health_uniquely_positioned_to_fulfill_the_world_s_need_for_medicine
452,2019-07-23,382.0,171.0,0.3815551530170793,0.2702834798287959,Medicines,"FDA Approves Pfizer’s Biosimilar, RUXIENCE™ (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions",https://www.pfizer.com//news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_ruxience_rituximab_pvvr_for_certain_cancers_and_autoimmune_conditions
453,2019-07-05,291.0,73.0,0.5989010972557662,0.2550805884687592,Research,Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels,https://www.pfizer.com//news/press-release/press-release-detail/sangamo_and_pfizer_announce_updated_phase_1_2_results_for_sb_525_investigational_hemophilia_a_gene_therapy_showing_sustained_increased_factor_viii_levels
454,2019-07-01,113.0,21.0,0.686567159055469,0.28571428510508684,Finance,Pfizer Completes Acquisition of Therachon,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_completes_acquisition_of_therachon
455,2019-07-01,187.0,41.0,0.640350874384426,0.28078817699410324,Research,"Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_phase_4_study_of_crisaborole_ointment_2_in_children_aged_3_months_to_less_than_24_months_with_mild_to_moderate_atopic_dermatitis
456,2019-06-28,196.0,84.0,0.3999999985714286,0.2898550721637111,Research,Pfizer Announces Results from Phase 3 Trial of Revatio® (Sildenafil Citrate) in Newborns with Persistent Pulmonary Hypertension,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_results_from_phase_3_trial_of_revatio_sildenafil_citrate_in_newborns_with_persistent_pulmonary_hypertension
457,2019-06-28,202.0,75.0,0.4584837528574594,0.26737451711643384,Research,Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD),https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_initial_clinical_data_on_phase_1b_gene_therapy_study_for_duchenne_muscular_dystrophy_dmd
458,2019-06-28,278.0,133.0,0.35279805266959113,0.2540173051582093,Medicines,"Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_u_s_fda_approval_for_its_oncology_biosimilar_zirabev_bevacizumab_bvzr
459,2019-06-27,73.0,11.0,0.7380952293083901,0.3021582722943947,Leadership,Scott Gottlieb Elected to Pfizer’s Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/scott_gottlieb_elected_to_pfizer_s_board_of_directors
460,2019-06-27,46.0,4.0,0.8399999832000004,0.33333333111111113,Finance,Pfizer Declares Third-Quarter 2019 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_third_quarter_2019_dividend
461,2019-06-21,295.0,133.0,0.37850467201283955,0.25280567025823647,Medicines,European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer,https://www.pfizer.com//news/press-release/press-release-detail/european_commission_approves_talzenna_talazoparib_for_patients_with_inherited_germline_brca_mutated_locally_advanced_or_metastatic_breast_cancer
462,2019-06-18,16.0,1.0,0.8823528892733594,0.19101123380886253,Finance,Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_july_30_conference_call_with_analysts-0
463,2019-06-17,362.0,87.0,0.6124721589922669,0.2644287395380278,Finance,Pfizer to Acquire Array BioPharma,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_to_acquire_array_biopharma
464,2019-06-12,315.0,169.0,0.3016528919387337,0.2602150536235403,Medicines,"Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_results_from_xeljanz_xr_tofacitinib_oral_shift_study_the_first_phase_3b_4_study_to_evaluate_methotrexate_withdrawal_with_a_jak_inhibitor
465,2019-06-05,138.0,31.0,0.6331360909281888,0.27346278272902463,Leadership,"Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development",https://www.pfizer.com//news/press-release/press-release-detail/jeff_settleman_ph_d_joins_pfizer_to_lead_oncology_research_development
466,2019-05-24,157.0,73.0,0.36521738971644613,0.29003783065569,Medicines,Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_top_line_results_from_phase_3_trial_of_lyrica_pregabalin_in_primary_generalized_tonic_clonic_seizures
467,2019-05-15,200.0,45.0,0.6326530586422324,0.2642934193481193,Research,Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_oncology_to_showcase_new_data_from_innovative_science_that_address_patient_needs_at_asco_2019_annual_meeting
468,2019-05-15,181.0,57.0,0.5210084011722336,0.2446043162953707,Research,"Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_pf_04965842_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis
469,2019-05-14,467.0,214.0,0.3715124810991006,0.24373657829501197,Medicines,FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/fda_approves_bavencio_avelumab_plus_inlyta_axitinib_combination_for_patients_with_advanced_renal_cell_carcinoma
470,2019-05-09,137.0,18.0,0.7677419305306973,0.2986512518330419,Finance,"Pfizer Opens New State-Of-The-Art Biologics Clinical Manufacturing Facility In Andover, Massachusetts",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_opens_new_state_of_the_art_biologics_clinical_manufacturing_facility_in_andover_massachusetts
471,2019-05-08,165.0,38.0,0.625615760464947,0.2569620249911873,Finance,Pfizer Acquires Clinical-Stage Biotech Therachon,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_acquires_clinical_stage_biotech_therachon
472,2019-05-07,317.0,109.0,0.488262909651965,0.2832446806627362,Medicines,European Commission Approves LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/european_commission_approves_lorviqua_lorlatinib_for_certain_adult_patients_with_previously_treated_alk_positive_advanced_non_small_cell_lung_cancer
473,2019-05-06,250.0,77.0,0.5290519861496881,0.2745591937241316,Medicines,"U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease",https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_vyndaqel_and_vyndamax_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease
474,2019-04-30,,,,,Finance,PFIZER REPORTS FIRST-QUARTER 2019 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_first_quarter_2019_results
475,2019-04-26,216.0,75.0,0.4845360808091544,0.27145522362737384,Medicines,Pfizer Receives Positive CHMP Opinion for TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_talzenna_talazoparib_for_patients_with_inherited_germline_brca_mutated_locally_advanced_or_metastatic_breast_cancer
476,2019-04-25,109.0,18.0,0.7165354274288549,0.2960372953472324,Finance,Pfizer Hosts Annual Meeting of Shareholders,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_hosts_annual_meeting_of_shareholders-6
477,2019-04-18,194.0,78.0,0.4264705866673876,0.2628019321132348,Research,Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_lilly_announce_top_line_results_from_long_term_phase_3_study_of_tanezumab_in_patients_with_osteoarthritis
478,2019-04-18,50.0,4.0,0.8518518360768179,0.32142856951530613,Finance,Pfizer Invites Public to Listen to Webcast of April 25 Annual Meeting of Shareholders,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_listen_to_webcast_of_april_25_annual_meeting_of_shareholders-0
479,2019-04-13,206.0,81.0,0.43554006816884994,0.2175890824733972,Research,Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_presentation_of_data_from_a_phase_2_study_of_its_20_valent_pneumococcal_conjugate_vaccine_candidate_being_investigated_for_the_prevention_of_invasive_disease_and_pneumonia_in_adults_aged_18_years
480,2019-04-04,248.0,93.0,0.4545454532124767,0.2738955821093208,Medicines,"U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer",https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_ibrance_palbociclib_for_the_treatment_of_men_with_hr_her2_metastatic_breast_cancer
481,2019-04-03,307.0,111.0,0.4688995204093313,0.29210342397477046,Medicines,VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/vizimpro_dacomitinib_receives_marketing_authorization_in_european_union_eu_for_the_first_line_treatment_of_adult_patients_with_egfr_mutated_non_small_cell_lung_cancer
482,2019-04-02,234.0,45.0,0.6774193524106833,0.25833333309413575,Research,Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/sangamo_and_pfizer_announce_phase_1_2_interim_data_for_investigational_hemophilia_a_gene_therapy
483,2019-03-20,183.0,59.0,0.5123966920975344,0.29548229512151125,Finance,Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_secures_exclusive_option_to_acquire_gene_therapy_company_vivet_therapeutics
484,2019-03-19,347.0,153.0,0.387999999224,0.24801587289284927,Research,"Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer",https://www.pfizer.com//news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_announce_discontinuation_of_phase_iii_javelin_ovarian_parp_100_trial_in_previously_untreated_advanced_ovarian_cancer
485,2019-03-19,16.0,1.0,0.8823528892733594,0.19101123380886253,Finance,Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_april_30_conference_call_with_analysts-0
486,2019-03-17,332.0,108.0,0.5090909079338843,0.20803782496073864,Research,AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention,https://www.pfizer.com//news/press-release/press-release-detail/augustus_demonstrates_favorable_safety_results_of_eliquis_versus_vitamin_k_antagonists_in_non_valvular_atrial_fibrillation_patients_with_acute_coronary_syndrome_and_or_undergoing_percutaneous_coronary_intervention
487,2019-03-11,209.0,85.0,0.4217687060484058,0.2601769909201973,Medicines,"U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1",https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_pfizer_s_oncology_biosimilar_trazimera_trastuzumab_qyyp_a_biosimilar_to_herceptin_1
488,2019-03-08,343.0,166.0,0.3477406672932403,0.2482926828057109,Medicines,European Medicines Agency Validates Application for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/european_medicines_agency_validates_application_for_bavencio_avelumab_plus_inlyta_axitinib_for_the_treatment_of_advanced_renal_cell_carcinoma
489,2019-03-05,41.0,5.0,0.7826086786389418,0.20814479543825884,Finance,Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_pfizer_presentation_at_healthcare_conference-23
490,2019-03-04,115.0,14.0,0.7829457303647618,0.3200992547888356,Finance,"Pfizer Prices $5,000,000,000 Debt Offering",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_prices_5_000_000_000_debt_offering-0
491,2019-03-01,264.0,101.0,0.44657534124225934,0.2769347494105199,Medicines,Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_lorviqua_lorlatinib_for_certain_adult_patients_with_previously_treated_alk_positive_advanced_non_small_cell_lung_cancer
492,2019-02-28,176.0,58.0,0.5042735021184893,0.20726306447540913,Research,Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_serotypes_included_in_20_valent_pneumococcal_conjugate_vaccine_candidate_being_investigated_for_the_prevention_of_invasive_disease_and_pneumonia_in_adults_aged_18_years_and_older
493,2019-02-19,215.0,18.0,0.845493558603032,0.3493253368076082,Research,Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials,https://www.pfizer.com//news/press-release/press-release-detail/ochsner_health_system_and_pfizer_partner_to_develop_innovative_models_for_clinical_trials
494,2019-02-19,228.0,78.0,0.49019607682942457,0.27592425583775987,Medicines,"Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®*",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_european_approval_for_zirabev_bevacizumab_a_biosimilar_to_avastin
495,2019-02-19,215.0,90.0,0.4098360642300457,0.29047619019954646,Research,Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_lilly_announce_top_line_results_from_phase_3_study_of_tanezumab_in_chronic_low_back_pain
496,2019-02-16,556.0,285.0,0.3222354336239769,0.2289681458674195,Research,Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in The New England Journal of Medicine,https://www.pfizer.com//news/press-release/press-release-detail/pivotal_phase_iii_data_for_bavencio_avelumab_plus_inlyta_axitinib_in_advanced_renal_cell_carcinoma_published_in_the_new_england_journal_of_medicine
497,2019-02-12,73.0,5.0,0.8717948606180146,0.22413793039040825,Partnerships,"G-CON Manufacturing Delivers New PCMM POD® With Tablet Coating Capability to Pfizer Inc.’s  Groton, Conn. Site",https://www.pfizer.com//news/press-release/press-release-detail/g-con-manufacturing-delivers-new-pcmm-podr-tablet-coating
498,2019-02-11,514.0,261.0,0.32645161248199794,0.22969768813583352,Medicines,FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/fda_accepts_sbla_and_grants_priority_review_for_bavencio_avelumab_plus_inlyta_axitinib_for_the_treatment_of_advanced_renal_cell_carcinoma
499,2019-02-11,280.0,150.0,0.3023255806922661,0.26658400479443023,Research,Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/phase_3_arches_trial_shows_xtandi_enzalutamide_significantly_improved_radiographic_progression_free_survival_in_men_with_metastatic_hormone_sensitive_prostate_cancer
500,2019-02-04,190.0,59.0,0.5261044155578136,0.37219730886069163,Responsibility,The Union For International Cancer Control And Pfizer Announce New Phase Of Global Grants Initiative Supporting Metastatic Breast Cancer Patients,https://www.pfizer.com//news/press-release/press-release-detail/the_union_for_international_cancer_control_and_pfizer_announce_new_phase_of_global_grants_initiative_supporting_metastatic_breast_cancer_patients
501,2019-02-01,276.0,101.0,0.46419098020108496,0.286474163916053,Medicines,Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_vizimpro_dacomitinib_for_the_first_line_treatment_of_adult_patients_with_locally_advanced_or_metastatic_non_small_cell_lung_cancer_with_egfr_activating_mutations
502,2019-01-29,,,,,Finance,PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_fourth_quarter_and_full_year_2018_results
503,2019-01-29,214.0,72.0,0.4965034947674703,0.273946359890856,Research,Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_lilly_announce_top_line_results_from_second_phase_3_study_of_tanezumab_in_osteoarthritis_pain
504,2019-01-14,192.0,60.0,0.5238095217309146,0.2566191443415284,Medicines,US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy,https://www.pfizer.com//news/press-release/press-release-detail/us_fda_accepts_regulatory_submissions_for_review_of_tafamidis_to_treat_transthyretin_amyloid_cardiomyopathy
505,2019-01-09,55.0,19.0,0.4864864799123449,0.21637426837317467,Partnerships,eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-inClass Inhibitors of eIF4E to Treat Multiple Cancer Types,https://www.pfizer.com//news/press-release/press-release-detail/effector-enters-agreement-pfizer-inc-develop-novel-first-
506,2019-01-07,70.0,10.0,0.7499999906250001,0.29411764597750867,Partnerships,CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model  of the Immune System for Drug Discovery,https://www.pfizer.com//news/press-release/press-release-detail/cytoreason-signs-collaboration-agreement-pfizer-inc-utilize
507,2019-01-03,153.0,51.0,0.49999999754901964,0.2428571425680272,Research,"Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_initiates_phase_2b_3_clinical_trial_for_pf_06651600_an_oral_jak3_inhibitor_for_the_treatment_of_patients_with_moderate_to_severe_alopecia_areata
508,2018-12-21,313.0,159.0,0.32627118574942543,0.26576576561612286,Research,"Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer",https://www.pfizer.com//news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_provide_update_on_javelin_ovarian_100_trial_of_avelumab_in_previously_untreated_advanced_ovarian_cancer
509,2018-12-20,85.0,23.0,0.5740740687585735,0.24942263221842348,Research,Independent Data Monitoring Committee Recommends Discontinuation of the Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Following Planned Interim Analysis,https://www.pfizer.com//news/press-release/press-release-detail/independent_data_monitoring_committee_recommends_discontinuation_of_the_phase_2b_strive_clinical_trial_of_staphylococcus_aureus_vaccine_following_planned_interim_analysis
510,2018-12-20,277.0,133.0,0.351219511338489,0.276094275908354,Research,Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/astellas_and_pfizer_announce_positive_top_line_results_from_phase_3_arches_trial_of_xtandi_enzalutamide_in_men_with_metastatic_hormone_sensitive_prostate_cancer
511,2018-12-18,149.0,28.0,0.6836158153468033,0.22180451100024498,Partnerships,Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global Consumer Healthcare Company,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_glaxosmithkline_announce_joint_venture_to_create_a_premier_global_consumer_healthcare_company
512,2018-12-18,16.0,1.0,0.8823528892733594,0.18478260668714558,Finance,Pfizer Invites Public to View and Listen to Webcast of January 29 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_january_29_conference_call_with_analysts-0
513,2018-12-17,77.0,21.0,0.5714285655976677,0.21444201265986432,Partnerships,Kineta Enters Research Collaboration and License Agreement  with Pfizer to Develop New Cancer Immunotherapies,https://www.pfizer.com//news/press-release/press-release-detail/kineta-enters-research-collaboration-and-license-agreement
514,2018-12-14,77.0,11.0,0.7499999914772728,0.27586206810074587,Finance,Pfizer Declares First-Quarter 2019 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_first_quarter_2019_dividend
515,2018-12-14,152.0,36.0,0.6170212733137166,0.2865853654167906,Medicines,"Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab)",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_oncology_biosimilar_zirabev_bevacizumab
516,2018-12-14,138.0,22.0,0.72499999546875,0.2601626012029876,Research,Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_initiates_phase_3_program_for_20_valent_pneumococcal_conjugate_vaccine_for_the_prevention_of_invasive_disease_and_pneumonia_in_adults_aged_18_years_and_older
517,2018-12-02,185.0,34.0,0.6894977137465857,0.2963464136720617,Research,"Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_positive_26_week_data_for_pf_05280586_a_potential_biosimilar_to_rituximab_at_the_american_society_of_hematology_annual_meeting
518,2018-11-30,109.0,14.0,0.7723577172979047,0.29710144855772597,Partnerships,Pfizer Reaches a Global Agreement with AbbVie,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reaches_a_global_agreement_with_abbvie
519,2018-11-27,108.0,50.0,0.3670886052715911,0.28884826272605435,Medicines,Pfizer Receives Six Months Pediatric Exclusivity for LYRICA® (pregabalin),https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_six_months_pediatric_exclusivity_for_lyrica_pregabalin
520,2018-11-21,281.0,86.0,0.5313351484159805,0.26421886230077835,Medicines,U.S. FDA Approves DAURISMO™ (glasdegib) for Adult Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML) for Whom Intensive Chemotherapy is Not an Option,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_daurismo_glasdegib_for_adult_patients_with_newly_diagnosed_acute_myeloid_leukemia_aml_for_whom_intensive_chemotherapy_is_not_an_option
521,2018-11-19,357.0,185.0,0.3173431728462303,0.257237778710376,Research,"Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer",https://www.pfizer.com//news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_provide_update_on_avelumab_in_platinum_resistant_refractory_ovarian_cancer
522,2018-11-02,473.0,205.0,0.3952802354051914,0.27360774807360466,Medicines,U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_lorbrena_lorlatinib_for_previously_treated_alk_positive_metastatic_nsclc
523,2018-10-30,,,,,Finance,PFIZER REPORTS THIRD-QUARTER 2018 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_third_quarter_2018_results
524,2018-10-28,128.0,36.0,0.5609756063355146,0.2918149460999734,Research,Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_clinical_development_agreement_with_novartis_to_advance_the_treatment_of_nash
525,2018-10-25,54.0,16.0,0.5428571351020409,0.26923076819526626,Partnerships,CANCER THERAPEUTICS CRC SIGNS AGREEMENT TO ENABLE PFIZER TO DEVELOP NOVEL  CANCER DRUGS,https://www.pfizer.com//news/press-release/press-release-detail/cancer-therapeutics-crc-signs-agreement-enable-pfizer
526,2018-10-23,229.0,64.0,0.563139929818635,0.26880733920292904,Research,Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients,https://www.pfizer.com//news/press-release/press-release-detail/complete_results_from_first_study_in_ongoing_phase_3_program_for_tanezumab_demonstrated_significant_improvement_in_pain_and_function_in_osteoarthritis_patients
527,2018-10-23,233.0,44.0,0.6823104668508647,0.33054892561987004,Partnerships,"Bain Capital and Pfizer Create Cerevel Therapeutics, New CNS Company",https://www.pfizer.com//news/press-release/press-release-detail/bain_capital_and_pfizer_create_cerevel_therapeutics_new_cns_company
528,2018-10-20,211.0,91.0,0.3973509920617517,0.23987291482138764,Research,"Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_overall_survival_data_from_paloma_3_trial_of_ibrance_palbociclib_in_patients_with_hr_her2_metastatic_breast_cancer
529,2018-10-16,59.0,8.0,0.7611940184896415,0.3453608229620576,Medicines,U.S. FDA Approves TALZENNA® (talazoparib),https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_talzenna_talazoparib
530,2018-10-09,123.0,27.0,0.6399999957333333,0.28846153790680473,Leadership,Pfizer Announces Executive Leadership Team,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_executive_leadership_team
531,2018-10-04,154.0,81.0,0.3106382965504753,0.2602436320484567,Finance,Pfizer to Award More Than $3 Million in Grants to Further Breast Cancer Research,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_to_award_more_than_3_million_in_grants_to_further_breast_cancer_research
532,2018-10-01,186.0,33.0,0.6986301337962094,0.3239644965621827,Leadership,Pfizer Announces CEO Succession,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_ceo_succession
533,2018-09-27,450.0,194.0,0.3975155273330504,0.27663230228666996,Medicines,U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_vizimpro_dacomitinib_for_the_first_line_treatment_of_patients_with_egfr_mutated_metastatic_non_small_cell_lung_cancer
534,2018-09-27,42.0,4.0,0.8260869385633275,0.31944444222608026,Finance,Pfizer Declares 34-Cent Fourth-Quarter 2018 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_34_cent_fourth_quarter_2018_dividend
535,2018-09-20,138.0,23.0,0.7142857098491571,0.25515055427075983,Vaccines,Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_granted_fda_breakthrough_therapy_designation_for_20_valent_pneumococcal_conjugate_vaccine_for_the_prevention_of_invasive_disease_and_pneumonia_in_adults_aged_18_years_and_older
536,2018-09-18,16.0,1.0,0.8823528892733594,0.18681318476029468,Finance,Pfizer Invites Public to View and Listen to Webcast of October 30 Conference Call with Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_october_30_conference_call_with_analysts-0
537,2018-09-18,224.0,66.0,0.5448275843281808,0.2575488452419637,Research,New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting,https://www.pfizer.com//news/press-release/press-release-detail/new_sub_group_analyses_from_the_tafamidis_phase_3_transthyretin_amyloid_cardiomyopathy_attr_act_study_presented_at_2018_hfsa_annual_scientific_meeting
538,2018-09-17,52.0,11.0,0.650793640463593,0.25819672025329216,Partnerships,ATOMWISE ENTERS INTO AN EVALUATION AGREEMENT WITH PFIZER,https://www.pfizer.com//news/press-release/press-release-detail/atomwise-enters-evaluation-agreement-pfizer
539,2018-09-14,163.0,53.0,0.5092592569015775,0.26024096354187837,Research,Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_presents_positive_phase_2_data_in_alopecia_areata_during_late_breaker_session_at_the_27th_european_academy_of_dermatology_and_venereology_eadv_congress
540,2018-09-12,59.0,21.0,0.4749999940625001,0.2424242416896235,Partnerships,System1 Announces a $25 Million Series A Funding to Advance  Integrated Technology Platform for Neurotherapeutics Discovery,https://www.pfizer.com//news/press-release/press-release-detail/system1-announces-25-million-series-funding-advance
541,2018-09-11,532.0,265.0,0.3350062731053874,0.23188827459066388,Research,BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients with Advanced Renal Cell Carcinoma in Phase III Study,https://www.pfizer.com//news/press-release/press-release-detail/bavencio_avelumab_plus_inlyta_axitinib_significantly_improved_progression_free_survival_in_previously_untreated_patients_with_advanced_renal_cell_carcinoma_in_phase_iii_study
542,2018-09-06,127.0,25.0,0.6710526271641275,0.2648083619079994,Partnerships,CYTOO enters into Research and Option Agreement with Pfizer to develop a  target discovery platform for Duchenne Muscular Dystrophy,https://www.pfizer.com//news/press-release/press-release-detail/cytoo-enters-research-and-option-agreement-pfizer-develop
543,2018-09-05,129.0,17.0,0.7671232824169638,0.3113006389950946,Partnerships,4D Molecular Therapeutics Raises $90 Million Series B Financing,https://www.pfizer.com//news/press-release/press-release-detail/4d-molecular-therapeutics-raises-90-million-series-b
544,2018-09-05,158.0,41.0,0.5879396955379915,0.23032407380749528,Medicines,"Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_breakthrough_therapy_designation_from_fda_for_pf_06651600_an_oral_jak3_inhibitor_for_the_treatment_of_patients_with_alopecia_areata
545,2018-09-04,113.0,14.0,0.7795275529171058,0.32315521546270937,Finance,"Pfizer Prices $5,000,000,000 Debt Offering",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_prices_5_000_000_000_debt_offering
546,2018-08-30,182.0,66.0,0.4677419335978148,0.3131313127359453,Research,Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_terminates_domagrozumab_pf_06252616_clinical_studies_for_the_treatment_of_duchenne_muscular_dystrophy
547,2018-08-22,257.0,112.0,0.3929539284743796,0.2705278590392024,Research,Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_astellas_amend_clinical_research_protocols_for_two_phase_3_trials_of_enzalutamide_in_patients_with_hormone_sensitive_prostate_cancer
548,2018-08-20,79.0,11.0,0.7555555471604939,0.25139664734246747,Finance,Pfizer Invites Public To View And Listen To Webcast Of August 27 Conference Call With Analysts And Investors To Review Tafamidis Data Presentation At ESC Congress 2018,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_august_27_conference_call_with_analysts_and_investors_to_review_tafamidis_data_presentation_at_esc_congress_2018
549,2018-08-16,162.0,31.0,0.6787564731670649,0.26438356128166635,Partnerships,BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza,https://www.pfizer.com//news/press-release/press-release-detail/biontech-signs-collaboration-agreement-pfizer-develop-mrna
550,2018-08-08,91.0,31.0,0.49180327465735024,0.2717149214438421,Partnerships,SANGAMO ANNOUNCES POSITIVE PRELIMINARY DATA FROM THE PHASE 1/2  ALTA STUDY EVALUATING SB-525 GENE THERAPY FOR HEMOPHILIA A,https://www.pfizer.com//news/press-release/press-release-detail/sangamo-announces-positive-preliminary-data-phase-12-alta
551,2018-08-01,337.0,142.0,0.4070981202357033,0.2712344279324833,Medicines,XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis,https://www.pfizer.com//news/press-release/press-release-detail/xeljanz_tofacitinib_citrate_receives_marketing_authorization_in_the_european_union_for_moderately_to_severely_active_ulcerative_colitis-0
552,2018-07-31,878.0,305.0,0.48436179164466453,0.27283210325811064,Finance,PFIZER REPORTS SECOND-QUARTER 2018 RESULTS,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_second_quarter_2018_results-0
553,2018-07-31,230.0,87.0,0.4511040995233309,0.28278322900732983,Medicines,"Pfizer Receives European Approval for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_european_approval_for_oncology_biosimilar_trazimera_trastuzumab-0
554,2018-07-24,134.0,21.0,0.7290322533610822,0.26863084875453924,Finance,"Pfizer to Build Cutting-Edge Sterile Injectable Facility in Michigan, Investing Nearly Half a Billion Dollars in U.S. Manufacturing, Creating More than 450 Jobs",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_to_build_cutting_edge_sterile_injectable_facility_in_michigan_investing_nearly_half_a_billion_dollars_in_u_s_manufacturing_creating_more_than_450_jobs-0
555,2018-07-20,186.0,51.0,0.569620250761096,0.259583789419952,Medicines,U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi),https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_pfizer_s_biosimilar_nivestym_filgrastim_aafi-0
556,2018-07-18,190.0,54.0,0.5573770468959958,0.2833914050134827,Research,Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_lilly_announce_positive_top_line_results_from_phase_3_trial_of_tanezumab_for_the_treatment_of_osteoarthritis_oa_pain
557,2018-07-16,226.0,77.0,0.4917491732945572,0.29446064111325493,Research,Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_initiates_pivotal_phase_3_program_for_investigational_hemophilia_b_gene_therapy-0
558,2018-07-13,320.0,162.0,0.32780082919543396,0.27017937204586356,Medicines,U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC),https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_approves_xtandi_enzalutamide_for_the_treatment_of_men_with_non_metastatic_castration_resistant_prostate_cancer_crpc-0
559,2018-07-11,202.0,33.0,0.7191489331100045,0.28143712541145255,Leadership,Pfizer to Organize for Future Growth,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_to_organize_for_future_growth-0
560,2018-06-28,312.0,135.0,0.39597315347657014,0.26465364105112277,Medicines,XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for Active Psoriatic Arthritis,https://www.pfizer.com//news/press-release/press-release-detail/xeljanz_tofacitinib_citrate_receives_marketing_authorisation_in_the_european_union_for_active_psoriatic_arthritis-0
561,2018-06-28,42.0,4.0,0.8260869385633275,0.32167831942882297,Finance,Pfizer Declares 34-Cent Third-Quarter 2018 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_34_cent_third_quarter_2018_dividend-0
562,2018-06-27,173.0,48.0,0.5656108571691817,0.27116564383906056,Research,U.S. FDA Grants Priority Review for Pfizer’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_grants_priority_review_for_pfizer_s_new_drug_application_for_glasdegib_in_patients_with_previously_untreated_acute_myeloid_leukemia-0
563,2018-06-25,217.0,87.0,0.4276315775406856,0.25061830152463455,Medicines,"Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_overall_survival_results_from_phase_3_paloma_3_trial_of_ibrance_palbociclib_in_hr_her2_metastatic_breast_cancer-0
564,2018-06-19,16.0,1.0,0.8823528892733594,0.18681318476029468,Finance,Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_july_31_conference_call_with_analysts-1
565,2018-06-12,192.0,65.0,0.49416342220169873,0.33638743411467614,Responsibility,Pfizer Announces Extension of Zithromax® Antibiotic Donation Program through 2025 to Help Eliminate World’s Leading Infectious Cause of Blindness,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_extension_of_zithromax_antibiotic_donation_program_through_2025_to_help_eliminate_world_s_leading_infectious_cause_of_blindness-0
566,2018-06-07,178.0,75.0,0.40711462289678013,0.2720430104601688,Medicines,U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_and_european_medicines_agency_accept_regulatory_submissions_for_review_of_talazoparib_for_metastatic_breast_cancer_patients_with_an_inherited_brca_mutation-1
567,2018-06-04,240.0,70.0,0.5483870950052029,0.2894491127082641,Research,Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations,https://www.pfizer.com//news/press-release/press-release-detail/dacomitinib_shows_more_than_seven_month_improvement_in_overall_survival_compared_to_an_established_therapy_in_advanced_nsclc_with_egfr_activating_mutations-0
568,2018-06-04,368.0,126.0,0.4898785415184645,0.2637479977235729,Medicines,Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab),https://www.pfizer.com//news/press-release/press-release-detail/two_year_update_of_pivotal_javelin_merkel_200_trial_shows_continued_durable_responses_with_bavencio_avelumab
569,2018-06-01,165.0,42.0,0.5942028956801793,0.2620253161240186,Medicines,"Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_oncology_biosimilar_trazimera_trastuzumab-0
570,2018-05-31,66.0,20.0,0.5348837147106545,0.23180592929432364,Partnerships,Cortexyme Completes $76 Million Series B Financing and Provides Update on Clinical Development Progress,https://www.pfizer.com//news/press-release/press-release-detail/cortexyme-completes-76-million-series-b-financing-and
571,2018-05-30,334.0,154.0,0.36885245826054824,0.26857457332494516,Medicines,Pfizer Announces U.S. FDA Approves XELJANZ® (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_u_s_fda_approves_xeljanz_tofacitinib_for_the_treatment_of_moderately_to_severely_active_ulcerative_colitis-0
572,2018-05-30,111.0,26.0,0.6204379516756354,0.3341463406484236,Responsibility,The Pfizer Foundation Announces $5 Million in Grants to Support Women and Families,https://www.pfizer.com//news/press-release/press-release-detail/the_pfizer_foundation_announces_5_million_in_grants_to_support_women_and_families-0
573,2018-05-29,359.0,153.0,0.4023437492141724,0.2682032476332094,Medicines,Pfizer’s XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0
574,2018-05-23,168.0,46.0,0.5700934552799372,0.27506426699863207,Research,FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy,https://www.pfizer.com//news/press-release/press-release-detail/fda_grants_breakthrough_therapy_designation_for_tafamidis_for_the_treatment_of_patients_with_transthyretin_cardiomyopathy-1
575,2018-05-22,255.0,94.0,0.461318050254103,0.2816787729768533,Research,A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+,https://www.pfizer.com//news/press-release/press-release-detail/a_study_analyzing_observational_data_shows_real_world_effectiveness_of_prevnar_13_in_adults_age_65-0
576,2018-05-22,190.0,59.0,0.5261044155578136,0.2718340608386091,Research,Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_begins_a_phase_1_2_study_to_evaluate_respiratory_syncytial_virus_rsv_vaccine-0
577,2018-05-21,218.0,62.0,0.5571428551530613,0.2609506055349948,Research,Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events,https://www.pfizer.com//news/press-release/press-release-detail/spark_therapeutics_and_pfizer_announce_data_from_15_participants_with_hemophilia_b_showing_persistent_and_sustained_factor_ix_levels_with_no_serious_adverse_events
578,2018-05-17,165.0,79.0,0.35245901494893844,0.28739693723510373,Medicines,LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint,https://www.pfizer.com//news/press-release/press-release-detail/lyrica_pregabalin_oral_solution_cv_phase_3_trial_in_pediatric_epilepsy_meets_primary_endpoint-0
579,2018-05-16,193.0,39.0,0.6637931005870987,0.24191866502406814,Research,Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_oncology_to_showcase_clinical_advances_from_its_growing_portfolio_and_research_pipeline_at_asco
580,2018-05-15,272.0,95.0,0.48228882702373616,0.27165062896250874,Medicines,Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_s_biosimilar_retacrit_epoetin_alfa_epbx_approved_by_u_s_fda
581,2018-05-08,76.0,7.0,0.8313252911888519,0.2686084133701993,Partnerships,XtalPi Inc. Announces Strategic Research Collaboration with Pfizer Inc. to Develop  Artificial Intelligence-Powered Molecular Modeling Technology for Drug Discovery,https://www.pfizer.com//news/press-release/press-release-detail/xtalpi-inc-announces-strategic-research-collaboration
582,2018-05-08,109.0,10.0,0.8319327661182121,0.2698412692293849,Partnerships,New project to enhance nanomedicine development,https://www.pfizer.com//news/press-release/press-release-detail/new-project-enhance-nanomedicine-development
583,2018-05-07,107.0,18.0,0.7119999943040001,0.26881720372297374,Partnerships,Wave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer,https://www.pfizer.com//news/press-release/press-release-detail/wave-life-sciences-highlights-progress-hepatic
584,2018-05-01,39.0,13.0,0.49999999038461557,0.22222222127255462,Partnerships,HUB Announces Collaboration with Pfizer Inc. on Human Gut Organoids for  IBD,https://www.pfizer.com//news/press-release/press-release-detail/hub-announces-collaboration-pfizer-inc-human-gut-organoids
585,2018-05-01,5.0,1.0,0.6666665555555741,0.1874999941406252,Finance,Pfizer Reports First-Quarter 2018 Results,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_first_quarter_2018_results
586,2018-04-26,101.0,16.0,0.7264957202863613,0.2954545447084481,Finance,Pfizer Hosts Annual Meeting of Shareholders,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_hosts_annual_meeting_of_shareholders-5
587,2018-04-23,193.0,49.0,0.5950413198552011,0.24795081941808317,Vaccines,Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_granted_fda_breakthrough_therapy_designation_for_trumenba_meningococcal_group_b_vaccine_for_the_prevention_of_invasive_meningococcal_b_disease_in_children_ages_1_to_9_years
588,2018-04-23,107.0,15.0,0.7540983544746037,0.29901960711024606,Medicines,Pfizer Provides Update on Proposed Trastuzumab Biosimilar,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_provides_update_on_proposed_trastuzumab_biosimilar
589,2018-04-23,207.0,69.0,0.4999999981884058,0.2703232122719655,Medicines,"MYLOTARG™ Approved In The EU For The Treatment Of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia In Combination With Chemotherapy",https://www.pfizer.com//news/press-release/press-release-detail/mylotarg_approved_in_the_eu_for_the_treatment_of_previously_untreated_de_novo_cd33_positive_acute_myeloid_leukemia_in_combination_with_chemotherapy
590,2018-04-19,48.0,4.0,0.8461538298816571,0.31901840295080736,Finance,Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_listen_to_webcast_of_april_26_annual_meeting_of_shareholders-0
591,2018-04-12,211.0,55.0,0.5864661632087739,0.2788259955148574,Research,Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_doses_first_patient_using_investigational_mini_dystrophin_gene_therapy_for_the_treatment_of_duchenne_muscular_dystrophy
592,2018-04-10,210.0,107.0,0.3249211346216999,0.26460767924490175,Research,Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_provides_update_on_phase_3_trial_of_axitinib_as_adjuvant_treatment_for_patients_at_high_risk_of_renal_cell_carcinoma_recurrence_after_surgery
593,2018-04-10,76.0,12.0,0.7272727190082646,0.3247232460342316,Finance,Pfizer Signs Lease for The Spiral at Hudson Yards in Manhattan,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_signs_lease_for_the_spiral_at_hudson_yards_in_manhattan
594,2018-04-04,223.0,79.0,0.47682119047410204,0.30753564123468874,Medicines,U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations,https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_and_european_medicines_agency_accept_regulatory_submissions_for_review_of_dacomitinib_to_treat_metastatic_non_small_cell_lung_cancer_with_egfr_activating_mutations
595,2018-04-03,295.0,56.0,0.6809116789717616,0.2746478871090392,Research,Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_and_allogene_therapeutics_enter_into_asset_contribution_agreement_for_pfizer_s_allogeneic_car_t_immuno_oncology_portfolio
596,2018-03-29,182.0,60.0,0.5041322293217676,0.28172293331580567,Research,Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_topline_results_from_phase_3_attr_act_study_of_tafamidis_in_patients_with_transthyretin_cardiomyopathy
597,2018-03-23,160.0,77.0,0.3502109689864516,0.324657533801839,Research,Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_top_line_results_from_a_study_of_chantix_champix_varenicline_in_adolescent_smokers
598,2018-03-19,271.0,130.0,0.35162094675406247,0.2662682601153597,Medicines,U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC),https://www.pfizer.com//news/press-release/press-release-detail/u_s_fda_grants_priority_review_for_a_supplemental_new_drug_application_snda_for_xtandi_enzalutamide_in_non_metastatic_castration_resistant_prostate_cancer_crpc
599,2018-03-19,61.0,6.0,0.8208955101358879,0.24452554655282646,Partnerships,BioDuro Collaboration with Pfizer Inc. Leads to Creation of a Shelf-Stable  Fluorosulfation Reagent,https://www.pfizer.com//news/press-release/press-release-detail/bioduro-collaboration-pfizer-inc-leads-creation-shelf
600,2018-03-12,91.0,48.0,0.30935251576005385,0.2598130836265176,Partnerships,BIOGEN TO ACQUIRE FROM PFIZER FIRST-IN-CLASS PHASE 2b READY ASSET  FOR COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA,https://www.pfizer.com//news/press-release/press-release-detail/biogen-acquire-pfizer-first-class-phase-2b-ready-asset
601,2018-03-11,300.0,68.0,0.6304347808955577,0.21533060256563452,Research,Findings Released from Largest Real-World Data Analysis of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants,https://www.pfizer.com//news/press-release/press-release-detail/findings_released_from_largest_real_world_data_analysis_of_non_valvular_atrial_fibrillation_patients_receiving_direct_oral_anticoagulants
602,2018-03-09,123.0,47.0,0.447058820899654,0.30357142802933673,Partnerships,AM‐Pharma announces Phase II study results of recAP in sepsis‐associated Acute  Kidney Injury,https://www.pfizer.com//news/press-release/press-release-detail/am-pharma-announces-phase-ii-study-results-recap-sepsis
603,2018-03-08,313.0,153.0,0.343347638748181,0.26598173500800126,Medicines,Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_favorable_outcome_of_fda_advisory_committee_meeting_on_xeljanz_tofacitinib_for_moderately_to_severely_active_ulcerative_colitis
604,2018-03-07,30.0,2.0,0.874999972656251,0.1658031079492067,Finance,Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_pfizer_presentation_at_healthcare_conference-22
605,2018-03-05,54.0,6.0,0.7999999866666669,0.2714932114412072,Leadership,Dan R. Littman Elected to Pfizer’s Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/dan_r_littman_elected_to_pfizer_s_board_of_directors
606,2018-03-02,43.0,11.0,0.5925925816186559,0.30508474403906927,Partnerships,Neofluidics Announces Collaboration with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/neofluidics-announces-collaboration-pfizer-inc
607,2018-02-28,65.0,21.0,0.5116279010275826,0.2336956515388705,Partnerships,Inserm announces research agreement with Pfizer Inc. to study rare neuromuscular  disease,https://www.pfizer.com//news/press-release/press-release-detail/inserm-announces-research-agreement-pfizer-inc-study-rare
608,2018-02-23,353.0,137.0,0.4408163256309871,0.25681341705617744,Medicines,"Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_two_hematology_medicines_mylotarg_and_bosulif
609,2018-02-23,290.0,123.0,0.40435835253181995,0.22061965800180572,Medicines,Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_update_on_european_marketing_authorization_application_for_sutent_sunitinib_in_adult_patients_at_high_risk_of_recurrent_renal_cell_carcinoma
610,2018-02-23,55.0,7.0,0.7741935359001043,0.2831050215383332,Leadership,Albert Bourla Elected to Pfizer’s Board of Directors,https://www.pfizer.com//news/press-release/press-release-detail/albert_bourla_elected_to_pfizer_s_board_of_directors
611,2018-02-14,132.0,19.0,0.7483443659050042,0.25208681093140767,Medicines,"Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis",https://www.pfizer.com//news/press-release/press-release-detail/pfizer_receives_breakthrough_therapy_designation_from_fda_for_pf_04965842_an_oral_jak1_inhibitor_for_the_treatment_of_patients_with_moderate_to_severe_atopic_dermatitis
612,2018-02-12,208.0,70.0,0.4964028759122199,0.2989247308613713,Research,"U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib",https://www.pfizer.com//news/press-release/press-release-detail/u_s_eu_and_japan_health_authorities_accept_regulatory_submissions_for_review_of_pfizer_s_third_generation_alk_inhibitor_lorlatinib
613,2018-02-05,291.0,149.0,0.32272727199380163,0.27194066732265715,Research,Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer,https://www.pfizer.com//news/press-release/press-release-detail/phase_3_prosper_trial_shows_xtandi_enzalutamide_significantly_reduced_the_risk_of_metastasis_or_death_by_71_percent_in_men_with_non_metastatic_castration_resistant_prostate_cancer
614,2018-01-30,9.0,1.0,0.7999999200000081,0.24999999375000018,Finance,Pfizer Reports Fourth-Quarter and Full-Year 2017 Results,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_reports_fourth_quarter_and_full_year_2017_results
615,2018-01-24,126.0,23.0,0.6912751631458043,0.27140254959671667,Medicines,Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_for_potential_biosimilar_to_rituxan_mabthera
616,2018-01-22,27.0,15.0,0.2857142789115648,0.2176165791833338,Partnerships,MINDIMMUNE THERAPEUTICS TO CONDUCT RESEARCH ON SPECIALIZED IMMUNE CELLS WITH PFIZER INC.,https://www.pfizer.com//news/press-release/press-release-detail/mindimmune-therapeutics-conduct-research-specialized-immune
617,2018-01-19,238.0,64.0,0.5761589384895399,0.2682060388381829,Research,Survey of Ulcerative Colitis Patients and Gastroenterologists Indicates that Symptoms May Create a New Reality for Patients,https://www.pfizer.com//news/press-release/press-release-detail/survey_of_ulcerative_colitis_patients_and_gastroenterologists_indicates_that_symptoms_may_create_a_new_reality_for_patients
618,2018-01-17,64.0,26.0,0.42222221753086425,0.24324324258582908,Partnerships,Circle Pharma announces publication in Journal of Medicinal Chemistry of results from  collaboration with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/circle-pharma-announces-publication-journal-medicinal
619,2018-01-09,79.0,6.0,0.8588235193079586,0.25147928919680684,Partnerships,Adapsyn Bioscience Completes Financing to Advance its Small Molecule Natural Products  Platform and Pipeline; Announces Research Collaboration with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/adapsyn-bioscience-completes-financing-advance-its-small
620,2018-01-08,48.0,28.0,0.2631578912742383,0.2483660122602418,Partnerships,Imcyse announces a research collaboration with  Pfizer Inc. in rheumatoid arthritis (RA),https://www.pfizer.com//news/press-release/press-release-detail/imcyse-announces-research-collaboration-pfizer-inc
621,2018-01-08,328.0,47.0,0.7493333313351112,0.2889060090224145,Partnerships,Regeneron Forms Consortium of Leading Life Sciences Companies to  Accelerate Largest Widely-Available ‘Big Data’ Human Sequencing Resource with UK Biobank,https://www.pfizer.com//news/press-release/press-release-detail/regeneron-forms-consortium-leading-life-sciences-companies
622,2018-01-08,174.0,12.0,0.8709677372528616,0.2985553767278405,Partnerships,"Alexandria Venture Investments Launches the Alexandria Seed Capital Platform, a Novel  and Innovative Seed-Stage Life Science Funding Model and a Natural Extension of  Alexandria LaunchLabs",https://www.pfizer.com//news/press-release/press-release-detail/alexandria-venture-investments-launches-alexandria-seed
623,2018-01-08,230.0,24.0,0.8110236188542377,0.31552794991859884,Finance,Pfizer Inc. Announces Expiration and Results of its Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Consents,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_inc_announces_expiration_and_results_of_its_tender_offer_for_its_5_750_per_cent_notes_due_2021_and_related_solicitation_of_consents
624,2018-01-08,163.0,21.0,0.7717391262405482,0.28351309663557306,Research,Pfizer Establishes New Partnering Model for Early-Stage Academic Research,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_establishes_new_partnering_model_for_early_stage_academic_research
625,2018-01-05,57.0,12.0,0.6521739035916826,0.2464285705484694,Partnerships,Distributed Bio Announces SuperHuman  Platform License Agreement with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/distributed-bio-announces-superhuman-platform-license-0
626,2018-01-05,57.0,12.0,0.6521739035916826,0.24731182707056693,Partnerships,Distributed Bio Announces SuperHuman  Platform License Agreement with Pfizer Inc.,https://www.pfizer.com//news/press-release/press-release-detail/distributed-bio-announces-superhuman-platform-license
627,2018-01-04,61.0,3.0,0.906249985839844,0.21768707408949975,Partnerships,Berkeley Lights Announces Research Collaboration and License Agreement with Pfizer,https://www.pfizer.com//news/press-release/press-release-detail/berkeley-lights-announces-research-collaboration-and
628,2018-01-03,199.0,51.0,0.5919999976320001,0.26680896449646857,Partnerships,Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS,https://www.pfizer.com//news/press-release/press-release-detail/sangamo_and_pfizer_announce_collaboration_for_development_of_zinc_finger_protein_gene_therapy_for_als
629,2017-12-18,76.0,11.0,0.7471264281939491,0.2824675315504301,Investments,Pfizer Declares First-Quarter 2018 Dividend,https://www.pfizer.com//news/press-release/press-release-detail/pfizer_declares_first_quarter_2018_dividend
630,2017-12-12,251.0,116.0,0.36784741044183267,0.2628939826197034,Medicines,U.S. Food And Drug Administration Extends Action Date For XELJANZ® (Tofacitinib) Supplemental New Drug Application In Ulcerative Colitis By Three Months,https://www.pfizer.com//news/press-release/press-release-detail/u_s_food_and_drug_administration_extends_action_date_for_xeljanz_tofacitinib_supplemental_new_drug_application_in_ulcerative_colitis_by_three_months
631,2017-11-21,121.0,50.0,0.4152046759344756,0.26348228002545104,Partnerships,Ground-breaking €34 million project to develop better test for liver disease,https://www.pfizer.com//news/press-release/press-release-detail/ground-breaking-eu34-million-project-develop-better-test
